In O O
both O O
species O O
( B-Drug_n O
- O O
) B-Drug_n O
- O O
NANM B-Drug_n B-Drug_n
but O O
not O O
( O O
+ B-Drug_n O
) O O
- O O
NANM B-Drug_n B-Drug_n
antagonized O O
the O O
rate O O
- O O
decreasing O O
effects O O
of O O
morphine B-Drug B-Drug
on O O
FI O O
and O O
FR O O
responding O O
. O O

In O O
conclusion O O
we O O
demonstrated O O
an O O
isolated O O
effect O O
of O O
calcium B-Drug B-Drug
( O O
as O O
chloride O O
) O O
on O O
absorption O O
of O O
9 O O
mg O O
of O O
iron O B-Drug
provided O O
as O O
nonheme B-Drug B-Drug
( O O
as O O
sulfate O B-Drug
) O O
and O O
heme B-Drug B-Drug
( O O
as O O
CRBC O O
) O O
iron B-Drug B-Drug
. O O

The O O
distribution O O
of O O
renal O O
replacement O O
therapies O O
were O O
: O O
9 O O
peritoneal O O
dialysis O O
9 O O
conventional O O
hemodialysis O O
and O O
9 O O
nocturnal O O
hemodialysis O O
. O O

cases O O
occurred O O
between O O
the O O
9th O O
and O O
the O O
9th O O
day O O
of O O
treatment O O
. O O

For O O
conditioned O O
place O O
preference O O
subjects O O
were O O
conditioned O O
for O O
9 O O
consecutive O O
days O O
( O O
P9 O O
- O O
9 O O
) O O
with O O
amphetamine B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
or O O
saline O O
and O O
a O O
drug O O
- O O
free O O
preference O O
test O O
was O O
conducted O O
at O O
P9 O O
. O O

On O O
the O O
other O O
hand O O
the O O
enhanced O O
secretion O O
of O O
colonic O O
fluid O O
by O O
dmPGE9 B-Drug_n B-Drug
given O O
intraluminally O O
was O O
only O O
half O O
of O O
that O O
in O O
control O O
rats O O
whereas O O
the O O
colonic O O
transit O O
- O O
enhancing O O
effect O O
of O O
dmPGE9 B-Drug_n B-Drug_n
in O O
cecectomized O O
rats O O
was O O
more O O
pronounced O O
than O O
in O O
control O O
rats O O
at O O
9 O O
but O O
not O O
at O O
9 O O
min O O
after O O
its O O
administration O O
. O O

Recovery O O
from O O
9 O O
% O O
twitch O O
to O O
9 O O
% O O
fade O O
recovery O O
took O O
9 O O
+ O O
/ O O
- O O
9 O O
min O O
for O O
atracurium B-Drug B-Drug
alone O O
and O O
9 O O
+ O O
/ O O
- O O
9 O O
min O O
for O O
atracurium B-Drug B-Drug
plus O O
gentamycin B-Drug B-Drug
. O O

Differences O O
in O O
iron B-Drug B-Drug
balance O O
were O O
only O O
observed O O
between O O
both O O
dietary O O
concentrations O O
showing O O
a O O
higher O O
absolute O O
but O O
a O O
lower O O
relative O O
absorption O O
as O O
well O O
as O O
retention O O
in O O
the O O
groups O O
fed O O
further O O
Fe B-Drug B-Drug
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
9 O O
WORDS O O
) O O

( O O
9 O O
) O O
microtubules O O
per O O
axon O O
. O O

Today O O
pharmacological O O
magnesium B-Drug B-Drug
therapy O O
mainly O O
concerns O O
the O O
obstetrical O O
cardiological O O
and O O
anaesthesiological O O
fields O O
. O O

For O O
a O O
9 O O
- O O
fold O O
range O O
of O O
everolimus B-Drug B-Drug
doses O O
there O O
were O O
no O O
differential O O
effects O O
on O O
cyclosporine B-Drug B-Drug
dosing O O
or O O
pharmacokinetics O O
. O O

The O O
evidence O O
for O O
a O O
role O O
for O O
norepinephrine O O
and O O
dopamine O O
and O O
the O O
effects O O
of O O
antihistaminics B-Group B-Drug
on O O
them O O
are O O
less O O
well O O
established O O
. O O

Internal O O
application O O
of O O
InsP9 B-Drug_n B-Drug
( O O
9 O O
microM O O
) O O
increased O O
intracellular O O
Ca O O
( O O
9+ O O
) O O
concentration O O
( O O
[ O O
Ca O O
( O O
9+ O O
) O O
] O O
( O O
i O O
) O O
) O O
and O O
activated O O
the O O
Ca O O
( O O
9+ O O
) O O
- O O
dependent O O
K O O
( O O
+ O O
) O O
current O O
. O O

9 O O
% O O
( O O
9 O O
% O O
CI O O
+ O O
/ O O
- O O
9 O O
) O O
of O O
the O O
total O O
PICR O O
could O O
be O O
avoided O O
by O O
simple O O
recommendations O O
; O O

Mice O O
from O O
the O O
9th O O
generation O O
of O O
three O O
lines O O
divergently O O
selected O O
for O O
response O O
to O O
pentobarbital B-Drug B-Drug
- O O
induced O O
sedation O O
times O O
[ O O
long O O
- O O
sedation O O
time O O
( O O
LST O O
) O O
short O O
sedation O O
time O O
( O O
SST O O
) O O
and O O
randomly O O
bred O O
control O O
( O O
RBC O O
) O O
] O O
were O O
used O O
to O O
study O O
cocaine B-Drug B-Drug
- O O
induced O O
behavioral O O
sensitization O O
. O O

Analyses O O
of O O
this O O
sequence O O
however O O
usually O O
give O O
little O O
consideration O O
to O O
the O O
nature O O
of O O
the O O
target O O
cell O O
or O O
to O O
the O O
characteristics O O
of O O
the O O
resultant O O
tumors O O
. O O

After O O
one O O
day O O
fecal O O
as O O
well O O
as O O
urinary O O
excretion O O
of O O
both O O
elements O O
had O O
already O O
responded O O
to O O
the O O
dietary O O
treatments O O
with O O
constant O O
values O O
being O O
reached O O
after O O
approximately O O
three O O
days O O
. O O

Acetylcysteine B-Drug O
interference O O
with O O
urine O O
ketone O O
test O O
. O O

Atracurium B-Drug B-Drug
infusion O O
was O O
continued O O
for O O
a O O
third O O
hour O O
and O O
then O O
hoof O O
twitch O O
was O O
again O O
allowed O O
to O O
recover O O
spontaneously O O
to O O
9 O O
% O O
. O O

Intraventricular O O
injection O O
of O O
beta B-Drug_n B-Drug_n
- O O
endorphin B-Drug_n B-Drug_n
and O O
morphine B-Drug B-Drug
produced O O
an O O
inhibition O O
of O O
the O O
tail O O
- O O
flick O O
response O O
to O O
the O O
heat O O
stimulus O O
in O O
rats O O
. O O

Limited O O
comparative O O
data O O
in O O
patients O O
with O O
high O O
viral O O
loads O O
treated O O
with O O
nevirapine B-Drug B-Drug
- O O
or O O
delavirdine B-Drug B-Drug_n
- O O
based O O
regimens O O
currently O O
exist O O
. O O

Glutathione O B-Drug
- O O
S O B-Drug_n
- O O
transferase O O
( O O
GST O O
) O O
activity O O
however O O
did O O
not O O
differ O O
from O O
control O O
values O O
for O O
any O O
dose O O
or O O
at O O
any O O
time O O
point O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
. O O

Still O O
other O O
pathways O O
have O O
been O O
proposed O O
. O O

In O O
period O O
A O O
all O O
volunteers O O
took O O
9 O O
mg O O
of O O
tolbutamide B-Drug B-Drug
orally O O
. O O

N B-Drug_n B-Drug_n
- O O
methyllevallorphan B-Drug_n B-Drug_n
( O O
9 O O
mg O O
/ O O
kg O O
s.c. O O
) O O
completely O O
antagonized O O
the O O
inhibitory O O
effect O O
of O O
loperamide B-Drug B-Drug
and O O
partly O O
antagonized O O
the O O
effect O O
of O O
morphine B-Drug B-Drug
. O O

Sprague O O
- O O
Dawley O O
rats O O
were O O
treated O O
with O O
quinpirole B-Drug_n B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
or O O
saline O O
from O O
postnatal O O
days O O
( O O
P O O
) O O
9 O O
to O O
P9 O O
and O O
raised O O
to O O
adolescence O O
. O O

The O O
results O O
generated O O
to O O
date O O
in O O
clinical O O
pharmacokinetic O O
studies O O
with O O
fluvastatin B-Drug B-Drug
thus O O
support O O
its O O
use O O
in O O
a O O
broad O O
population O O
of O O
hypercholesterolaemic O O
patients O O
. O O

Uncontrolled O O
hy O O
- O O
per O O
- O O
parathyroidism O O
causes O O
bone O O
marrow O O
fibrosis O O
leading O O
to O O
erythropoietin B-Drug B-Drug
( O O
EPO B-Drug O
) O O
resistance O O
. O O

Therapeutic O O
drug O O
monitoring O O
can O O
avoid O O
iatrogenic O O
alterations O O
caused O O
by O O
9mTc B-Drug B-Drug_n
- O O
methylene B-Drug B-Drug_n
diphosphonate I-Drug I-Drug_n
( O O
MDP O B-Drug_n
) O O
- O O
gentamicin B-Drug B-Drug
interaction O O
. O O

It O O
will O O
compete O O
with O O
clopidogrel B-Drug B-Drug
( O O
Plavix B-Brand B-Drug
) O O
and O O
prasugrel B-Drug O
( O O
Effient B-Brand O
) O O
for O O
such O O
use O O
. O O

When O O
combined O O
with O O
ofloxacin B-Drug B-Drug
KRM B-Drug_n I-Drug
- O O
9 B-Drug_n O
exhibited O O
strong O O
synergistic O O
activity O O
while O O
only O O
additive O O
effects O O
were O O
observed O O
with O O
the O O
combination O O
of O O
rifampicin B-Drug B-Drug
( O O
or O O
rifabutin B-Drug B-Drug
) O O
and O O
ofloxacin B-Drug B-Drug
. O O

phase O O
9 O O
( O O
days O O
9 O O
- O O
9 O O
) O O
: O O
fluoxetine B-Drug B-Drug
9 O O
mg O O
/ O O
day O O
; O O

Some O O
9 O O
% O O
of O O
a O O
single O O
dosage O O
of O O
fluvastatin B-Drug B-Drug
is O O
excreted O O
via O O
the O O
biliary O O
route O O
with O O
less O O
than O O
9 O O
% O O
of O O
this O O
being O O
the O O
parent O O
compound O O
. O O

All O O
the O O
animals O O
were O O
killed O O
at O O
the O O
end O O
of O O
the O O
9th O O
week O O
of O O
the O O
experiment O O
. O O

It O O
is O O
also O O
shown O O
that O O
after O O
9 O O
days O O
of O O
daily O O
administration O O
of O O
chlordiazepoxide B-Drug O
withdrawal O O
of O O
the O O
drug O O
not O O
only O O
re O O
- O O
results O O
in O O
almost O O
complete O O
loss O O
of O O
bar O O
- O O
press O O
response O O
in O O
the O O
E O O
- O O
strain O O
subjects O O
but O O
also O O
results O O
in O O
a O O
temporary O O
decrease O O
in O O
the O O
acquired O O
behavioral O O
response O O
of O O
the O O
stable O O
A O O
- O O
strain O O
subjects O O
. O O

While O O
9 B-Drug_n B-Drug_n
- O O
MC B-Drug_n B-Drug_n
and O O
ibogaine B-Drug_n B-Drug_n
have O O
similar O O
affinities O O
for O O
kappa O O
opioid O O
and O O
possibly O O
nicotinic O O
receptors O O
9 B-Drug_n O
- O O
MC B-Drug_n B-Drug_n
has O O
much O O
lower O O
affinities O O
than O O
ibogaine B-Drug_n O
for O O
NMDA O O
and O O
sigma O O
- O O
9 O O
receptors O O
sodium O B-Group
channels O I-Group
and O O
the O O
9 O O
- O O
HT O O
transporter O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
phenotype O O
of O O
a O O
tumor O O
that O O
results O O
from O O
a O O
pulse O O
of O O
a O O
chemical O O
carcinogen O O
may O O
depend O O
upon O O
the O O
target O O
cell O O
. O O

The O O
results O O
obtained O O
confirm O O
the O O
role O O
of O O
inflammatory O O
processes O O
in O O
parkinsonism O O
and O O
suggest O O
expediency O O
of O O
combined O O
pharmacotherapy O O
of O O
neurodegenerative O O
diseases O O
. O O

These O O
cells O O
express O O
the O O
vitamin O O
D O O
receptor O O
and O O
exhibit O O
doubling O O
times O O
comparable O O
to O O
the O O
parental O O
MCF O O
- O O
9 O O
cells O O
even O O
when O O
grown O O
in O O
9 O O
mM O O
9 B-Drug O
9 I-Drug O
( O O
OH B-Drug B-Drug
) O O
9D9 B-Drug B-Drug
. O O

In O O
both O O
sexes O O
of O O
swiss O O
albino O O
mice O O
; O O

The O O
behavioral O O
effects O O
of O O
the O O
stereoisomers O O
of O O
N B-Drug_n B-Drug_n
- O O
allylnormetazocine B-Drug_n B-Drug
( O O
NANM B-Drug_n B-Drug_n
) O O
were O O
compared O O
with O O
those O O
of O O
phencyclidine B-Drug_n B-Drug
( O O
PCP B-Drug_n B-Drug_n
) O O
in O O
pigeons O O
and O O
squirrel O O
monkeys O O
responding O O
under O O
a O O
multiple O O
fixed O O
- O O
interval O O
fixed O O
- O O
ratio O O
( O O
FI O O
FR O O
) O O
schedule O O
of O O
food O O
presentation O O
. O O

Carbamazepine B-Drug B-Drug
overdose O O
recognized O O
by O O
a O O
tricyclic B-Group O
antidepressant I-Group O
assay O O
. O O

Cobalt B-Drug O
excretion O O
was O O
enhanced O O
by O O
supplementary O O
cobalt B-Drug B-Drug
; O O

We O O
conclude O O
that O O
ADL B-Drug B-Drug
9 I-Drug I-Drug
- O O
9 B-Drug O
prevents O O
morphine B-Drug B-Drug
- O O
induced O O
increases O O
in O O
gastrointestinal O O
transit O O
time O O
by O O
means O O
of O O
selective O O
peripheral O O
opioid O O
anitagonism O O
without O O
affecting O O
central O O
opioid O O
analgesia O O
. O O

Rats O O
treated O O
with O O
neonatal O O
quinpirole B-Drug_n O
enhanced O O
time O O
spent O O
in O O
the O O
amphetamine B-Drug B-Drug
- O O
paired O O
context O O
compared O O
with O O
quinpirole B-Drug_n B-Drug_n
- O O
free O O
controls O O
conditioned O O
with O O
amphetamine B-Drug B-Drug
but O O
only O O
female O O
controls O O
conditioned O O
with O O
amphetamine B-Drug B-Drug
spent O O
more O O
time O O
in O O
the O O
drug O O
- O O
paired O O
context O O
compared O O
with O O
saline O O
- O O
treated O O
controls O O
. O O

[ O O
Multiple O O
occupational O O
exposure O O
to O O
solvents O O
] O O
This O O
article O O
review O O
papers O O
published O O
over O O
the O O
last O O
9 O O
years O O
on O O
multiple O O
occupational O O
exposure O O
to O O
solvents O O
. O O

Misonidazole B-Drug_n O
also O O
reduced O O
the O O
`` O O
early O O
'' O O

PCP B-Drug_n B-Drug_n
produced O O
distinctive O O
effects O O
in O O
each O O
task O O
: O O
it O O
substituted O O
for O O
the O O
training O O
dose O O
in O O
PCP B-Drug_n B-Drug_n
discrimination O O
and O O
it O O
increased O O
the O O
number O O
of O O
responses O O
with O O
short O O
( O O
< O O
9 O O
) O O
interresponse O O
times O O
as O O
well O O
as O O
increasing O O
overall O O
response O O
rates O O
in O O
the O O
DRL O O
schedule O O
. O O

METHOD O O
: O O
This O O
study O O
was O O
a O O
multicenter O O
randomized O O
double O O
- O O
blind O O
study O O
of O O
9 O O
patients O O
who O O
were O O
randomly O O
assigned O O
9:9:9 O O
to O O
receive O O
everolimus B-Drug B-Drug
tablets O O
at O O
doses O O
of O O
9 O O
mg O O
9 O O
mg O O
or O O
9 O O
mg O O
twice O O
daily O O
with O O
cyclosporine B-Drug B-Drug
and O O
prednisone B-Drug B-Drug
. O O

Further O O
studies O O
are O O
required O O
to O O
determine O O
the O O
potential O O
clinical O O
role O O
of O O
this O O
combination O O
regimen O O
as O O
a O O
therapeutic O O
alternative O O
for O O
certain O O
types O O
of O O
MRSA O O
infections O O
. O O

The O O
higher O O
verografine B-Drug B-Drug
and O O
iodamide B-Drug B-Drug
excretion O O
was O O
due O O
to O O
their O O
increased O O
renal O O
tubular O O
secretion O O
. O O

CASE O O
SUMMARY O O
: O O
A O B-Drug_n
9 O I-Drug_n
- O O
year O O
- O O
old O O
African O O
- O O
American O O
man O O
was O O
admitted O O
to O O
the O O
hospital O O
for O O
worsening O O
renal O O
failure O O
elevated O O
creatine O O
phosphokinase O O
diffuse O O
muscle O O
pain O O
and O O
severe O O
muscle O O
weakness O O
. O O

or O O
=9 O O
% O O
biocytin O O
was O O
included O O
in O O
the O O
recording O O
pipette O O
compared O O
with O O
neurons O O
recorded O O
without O O
biocytin O O
. O O

'' O O
hippocampal O O
- O O
independent O O
'' O O

[ O O
The O O
effect O O
of O O
cimetidine B-Drug B-Drug
on O O
the O O
renal O O
excretion O O
of O O
verografin B-Drug B-Drug
and O O
iodamide B-Drug B-Drug
in O O
dogs O O
] O O
The O O
intravenous O O
injection O O
of O O
cimetidine B-Drug B-Drug
in O O
a O O
dose O O
of O O
9 O O
mg O O
/ O O
kg O O
enhanced O O
verografine B-Drug B-Drug
and O O
iodamide B-Drug B-Drug
excretion O O
in O O
chronic O O
canine O O
experiments O O
. O O

Moreover O O
the O O
acquisition O O
of O O
tasks O O
that O O
are O O
facilitated O O
by O O
hippocampal O O
lesions O O
( O O
or O O
dysfunction O O
) O O
is O O
nevertheless O O
associated O O
in O O
intact O O
subjects O O
with O O
specific O O
neurobiological O O
alterations O O
in O O
the O O
hippocampus O O
. O O

Influence O O
of O O
coadministration O O
of O O
fluoxetine B-Drug B-Drug
on O O
cisapride B-Drug B-Drug
pharmacokinetics O O
and O O
QTc O O
intervals O O
in O O
healthy O O
volunteers O O
. O O

The O O
presence O O
of O O
the O O
radiopharmaceutical B-Group O
in O O
the O O
kidneys O O
along O O
with O O
an O O
increase O O
in O O
renal O O
retention O O
tend O O
to O O
produce O O
scintigraphic O O
results O O
that O O
falsely O O
identify O O
characteristics O O
related O O
to O O
diseases O O
such O O
as O O
renal O O
vascular O O
or O O
urinary O O
tract O O
obstruction O O
and O O
even O O
renal O O
cancer O O
. O O

The O O
next O O
chapter O O
presents O O
information O O
on O O
efficacy O O
and O O
pregnancy O O
outcomes O O
in O O
terms O O
of O O
pregnancy O O
rates O O
compliance O O
and O O
efficacy O O
ectopic O O
pregnancies O O
the O O
outcome O O
of O O
pregnancies O O
conceived O O
while O O
using O O
POCs B-Group O
and O O
fertility O O
following O O
discontinuation O O
. O O

Drug O O
regimens O O
in O O
patients O O
with O O
cardiovascular O O
disease O O
are O O
frequently O O
complex O O
and O O
can O O
be O O
significantly O O
affected O O
by O O
alterations O O
in O O
renal O O
function O O
. O O

The O O
latter O O
displayed O O
midazolam B-Drug B-Drug
clearances O O
similar O O
to O O
those O O
in O O
two O O
larger O O
cohorts O O
of O O
nonmatched O O
tacrolimus B-Drug B-Drug
- O O
treated O O
patients O O
( O O
n O O
= O O
9 O O
and O O
n O O
= O O
9 O O
) O O
and O O
to O O
those O O
receiving O O
a O O
calcineurin B-Group B-Group
inhibitor I-Group I-Group
- O O
free O O
regimen O O
( O O
n O O
= O O
9 O O
) O O
. O O

The O O
mechanism O O
( O O
) O O
of O O
altered O O
topo O O
I O O
expression O O
in O O
certain O O
tumor O O
types O O
is O O
unknown O O
but O O
may O O
be O O
related O O
to O O
the O O
central O O
importance O O
of O O
topoisomerases O O
in O O
proliferating O O
cell O O
functions O O
( O O
transcription O O
replication O O
etc O O
. O O
) O O
and O O
the O O
aberrant O O
and O O
chronic O O
activation O O
of O O
these O O
functions O O
as O O
a O O
result O O
of O O
specific O O
tumorigenic O O
alterations O O
. O O

AAV9 B-Drug_n B-Drug_n
- O O
mediated O O
retinal O O
transduction O O
is O O
improved O O
by O O
co O O
- O O
injection O O
of O O
heparinase B-Drug_n B-Group
III I-Drug_n I-Group
or O O
chondroitin B-Drug_n B-Group
ABC I-Drug_n I-Group
lyase I-Drug_n I-Group
. O O

Such O O
data O O
are O O
discussed O O
herein O O
with O O
emphasis O O
on O O
those O O
aspects O O
that O O
impact O O
on O O
the O O
clinical O O
use O O
of O O
the O O
calcium B-Group B-Drug
- O O
entry B-Group O
antagonists I-Group O
. O O

metabolic O O
interference O O
has O O
sometimes O O
been O O
observed O O
and O O
the O O
behaviour O O
of O O
the O O
biological O O
indicators O O
differs O O
from O O
what O O
would O O
be O O
expected O O
. O O

Selective O O
survival O O
in O O
pentazocine B-Drug B-Drug
and O O
tripelennamine B-Drug O
of O O
Pseudomonas O O
aeruginosa O O
serotype O O
O9 O O
from O O
drug O O
addicts O O
. O O

Modification O O
of O O
surface O O
histidine O O
residues O O
abolishes O O
the O O
cytotoxic O O
activity O O
of O O
Clostridium B-Drug_n B-Group
difficile I-Drug_n I-Group
toxin I-Drug_n B-Drug_n
A I-Drug_n I-Drug_n
. O O

Survanta B-Brand B-Drug
increased O O
the O O
extent O O
of O O
dissolution O O
of O O
budesonide B-Drug B-Drug
in O O
proportion O O
to O O
the O O
added O O
concentration O O
which O O
was O O
also O O
verified O O
by O O
equilibrium O O
solubilization O O
studies O O
. O O

The O O
fluoroquinolones B-Group O
for O O
urinary O O
tract O O
infections O O
: O O
a O O
review O O
. O O

In O O
monkeys O O
( B-Drug_n O
- O O
) B-Drug_n O
- O O
NANM B-Drug_n B-Drug_n
was O O
about O O
9 O O
times O O
more O O
potent O O
than O O
( O O
+ B-Drug_n O
) O O
- O O
NANM B-Drug_n B-Drug_n
in O O
decreasing O O
responding O O
whereas O O
in O O
pigeons O O
( B-Drug_n O
- O O
) B-Drug_n O
- O O
NANM B-Drug_n B-Drug_n
was O O
about O O
equipotent O O
with O O
( O O
+ B-Drug_n O
) O O
- O O
NANM B-Drug_n B-Drug_n
. O O

ALOX9 O O
was O O
the O O
most O O
down O O
- O O
regulated O O
gene O O
( O O
9 O O
- O O
fold O O
) O O
in O O
sensitive O O
cells O O
and O O
was O O
expressed O O
at O O
low O O
level O O
in O O
resistant O O
cells O O
. O O

These O O
results O O
suggest O O
that O O
the O O
hepatoxicity O O
of O O
ethanol B-Drug B-Drug
in O O
alcoholic O O
beverages O O
is O O
enhanced O O
by O O
interaction O O
with O O
its O O
congeners O O
and O O
acetaldehyde B-Drug_n B-Drug
; O O

In O O
contrast O O
preliminary O O
results O O
from O O
an O O
9 O O
- O O
week O O
controlled O O
study O O
suggested O O
risperidone B-Drug B-Drug
9 O O
to O O
9 O O
mg O O
/ O O
day O O
was O O
superior O O
to O O
olanzapine B-Drug B-Drug
9 O O
to O O
9 O O
mg O O
/ O O
day O O
against O O
positive O O
and O O
anxiety O O
/ O O
depressive O O
symptoms O O
( O O
p O O
< O O
9 O O
) O O
although O O
consistent O O
with O O
the O O
first O O
study O O
both O O
agents O O
demonstrated O O
similar O O
efficacy O O
on O O
measures O O
of O O
overall O O
psychopathology O O
. O O

phenobarbital B-Drug B-Drug
reduced O O
it O O
by O O
a O O
net O O
change O O
of O O
9 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
9 O O
% O O
) O O
at O O
9 O O
micromol O O
/ O O
L O O
. O O

No O O
change O O
in O O
phase O O
was O O
detected O O
although O O
the O O
aerosol O O
particles O O
appeared O O
to O O
contain O O
residual O O
solvent B-Group O
. O O

Morphine B-Drug B-Drug
analgesia O O
and O O
pupil O O
constriction O O
were O O
unaffected O O
by O O
ADL B-Drug B-Drug
9 I-Drug I-Drug
- O O
9 B-Drug O
and O O
differed O O
from O O
placebo O O
( O O
P O O
< O O
.9 O O
) O O
. O O

Dexamethasone B-Drug B-Drug
had O O
a O O
similar O O
effect O O
in O O
the O O
presence O O
of O O
insulin B-Drug O
. O O

In O O
contrast O O
in O O
isolated O O
single O O
pancreatic O O
acinar O O
cells O O
RR B-Drug_n B-Drug_n
had O O
no O O
effect O O
on O O
InsP9 B-Drug_n B-Drug_n
- O O
induced O O
responses O O
. O O

Interaction O O
of O O
the O O
constituents O O
of O O
alcoholic O O
beverages O O
in O O
the O O
promotion O O
of O O
liver O O
damage O O
. O O

The O O
therapeutic O O
outcome O O
for O O
T O O
- O O
cell O O
acute O O
lymphoblastic O O
leukemia O O
( O O
T O O
- O O
ALL O O
) O O
remains O O
poor O O
; O O

Like O O
ibogaine B-Drug_n B-Drug_n
( O O
9 O O
mg O O
/ O O
kg O O
) O O
9 B-Drug_n O
- O O
MC B-Drug_n B-Drug_n
( O O
9 O O
mg O O
/ O O
kg O O
) O O
decreases O O
the O O
intravenous O O
self O O
- O O
administration O O
of O O
morphine B-Drug B-Drug
and O O
cocaine B-Drug B-Drug
and O O
the O O
oral O O
self O O
- O O
administration O O
of O O
ethanol B-Drug B-Drug
and O O
nicotine B-Drug B-Drug
in O O
rats O O
; O O

We O O
have O O
selected O O
a O O
subclone O O
of O O
MCF O O
- O O
9 O O
cells O O
resistant O O
to O O
9 B-Drug O
9 I-Drug O
( O O
OH B-Drug B-Drug
) O O
9D9 B-Drug B-Drug
( O O
MCF O O
- O O
9D9Res O O
) O O
. O O

Rate O O
of O O
achievement O O
of O O
target O O
BP O O
with O O
fixed O O
combination O O
amlodipine B-Drug B-Drug
/ O O
valsartan B-Drug B-Drug
( O O
9 O O
% O O
) O O
was O O
comparable O O
with O O
that O O
on O O
traditional O O
therapy O O
( O O
9 O O
% O O
) O O
. O O

The O O
effects O O
of O O
DCG B-Drug_n B-Drug_n
- O O
IV B-Drug_n B-Drug_n
and O O
L B-Drug_n B-Drug_n
- O O
CCG B-Drug_n B-Drug_n
- O O
9 B-Drug_n B-Drug_n
upon O I-Drug_n
phencyclidine B-Drug_n I-Drug_n
( O O
PCP B-Drug_n B-Drug_n
) O O
- O O
induced O O
locomotion O O
and O O
behavioral O O
changes O O
in O O
mice O O
. O O

Eight O O
healthy O O
volunteers O O
were O O
randomized O O
in O O
an O O
open O O
- O O
label O O
two O O
- O O
way O O
crossover O O
study O O
to O O
receive O O
oxycodone B-Drug B-Drug
9 O O
mg O O
p.o O O
. O O

Although O O
the O O
proposed O O
methodology O O
for O O
deriving O O
experimental O O
designs O O
can O O
be O O
applied O O
to O O
any O O
nonlinear O O
regression O O
model O O
primary O O
focus O O
is O O
given O O
to O O
the O O
additive O O
and O O
nonadditive O O
independent O O
joint O O
action O O
( O O
IJA O O
) O O
models O O
for O O
individual O O
and O O
combined O O
exposures O O
proposed O O
by O O
Barton O O
Braunberg O O
and O O
Friedman O O
( O O
9 O O
) O O
. O O

Pantoprazole B-Drug B-Drug
has O O
a O O
much O O
weaker O O
effect O O
on O O
clopidogrel B-Drug B-Drug
's O O
pharmacokinetics O O
and O O
on O O
platelet O O
reactivity O O
during O O
concomitant O O
use O O
. O O

In O O
the O O
current O O
study O O
in O O
renal O O
allograft O O
recipients O O
we O O
used O O
intravenously O O
and O O
orally O O
administered O O
midazolam B-Drug B-Drug
as O O
a O O
drug O O
probe O O
to O O
assess O O
whether O O
the O O
study O O
drugs O O
at O O
doses O O
that O O
are O O
generally O O
used O O
in O O
clinical O O
practice O O
have O O
differential O O
effects O O
on O O
in O O
vivo O O
hepatic O O
and O O
first O O
- O O
pass O O
CYP9A O O
activities O O
. O O

Clopidogrel B-Drug B-Drug
is O O
expected O O
to O O
become O O
available O O
generically O O
in O O
the O O
US O O
within O O
the O O
next O O
few O O
months O O
. O O

Thus O O
in O O
addition O O
to O O
its O O
proposed O O
specific O O
information O O
processing O O
functions O O
( O O
i.e. O O
relational O O
) O O
the O O
hippocampus O O
would O O
play O O
a O O
role O O
in O O
addressing O O
information O O
to O O
the O O
brain O O
memory O O
system O O
that O O
in O O
a O O
given O O
situation O O
has O O
the O O
best O O
adaptive O O
value O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
9 O O
WORDS O O
) O O

Imipramine B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
moclobemide B-Drug O
( O O
9 O O
mg O O
/ O O
kg O O
) O O
clonazepam B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
fluoxetine B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
sertraline B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
or O O
vehicle O O
was O O
administered O O
. O O

The O O
goal O O
of O O
this O O
review O O
was O O
to O O
cite O O
primary O O
sources O O
for O O
virtually O O
all O O
research O O
specific O O
to O O
POPs O O
since O O
9 O O
. O O

We O O
have O O
demonstrated O O
appropriateness O O
of O O
inhospital O O
administration O O
of O O
fixed O O
amlodipine B-Drug B-Drug
/ O O
valsartan B-Drug B-Drug
combination O O
as O O
an O O
approach O O
allowing O O
to O O
achieve O O
target O O
BP O O
in O O
shorter O O
time O O
with O O
the O O
use O O
of O O
fewer O O
antihypertensive B-Group B-Group
drugs I-Group I-Group
and O O
diminishing O O
concealed O O
inefficacy O O
of O O
treatment O O
. O O

Ectopic O O
expression O O
of O O
ALOX9 O O
reduced O O
sensitivity O O
to O O
DZNep B-Drug_n B-Drug_n
in O O
H9 O O
cells O O
. O O

This O O
paper O O
attempts O O
to O O
provide O O
a O O
basis O O
for O O
the O O
understanding O O
and O O
identifications O O
of O O
important O O
drug O O
interactions O O
. O O

Questioning O O
revealed O O
the O O
child O O
was O O
taking O O
Infacol B-Brand O
drops O O
before O O
feeds O O
while O O
on O O
levothyroxine B-Drug B-Drug
. O O

Interaction O O
on O O
the O O
antinociceptive O O
effect O O
between O O
neurotensin B-Drug_n B-Drug
and O O
enkephalins B-Drug_n O
or O O
tuftsin B-Drug_n O
. O O

RESULTS O O
: O O
The O O
two O O
treatment O O
groups O O
were O O
well O O
matched O O
with O O
regard O O
to O O
patient O O
demographics O O
NHL O O
characteristics O O
HIV O O
status O O
and O O
treatment O O
i.e. O O
the O O
number O O
of O O
cycles O O
and O O
chemotherapy O O
dose O O
. O O

The O O
authors O O
examined O O
the O O
effect O O
of O O
the O O
cyclooxygenase O O
- O O
9 O B-Drug_n
( O O
COX O B-Drug_n
- O O
9 O O
) O O
inhibitor O O
rofecoxib B-Drug B-Drug
at O O
steady O O
state O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-Drug B-Drug
following O O
a O O
single O O
dose O O
in O O
healthy O O
subjects O O
. O O

Results O O
showed O O
that O O
GSLS B-Drug_n B-Group
significantly O O
increased O O
the O O
antibody O O
level O O
against O O
ND O O
in O O
the O O
serum O O
of O O
chickens O O
. O O

Concurrent O O
administration O O
of O O
indinavir B-Drug B-Drug
and O O
didanosine B-Drug B-Drug
significantly O O
reduces O O
the O O
level O O
of O O
exposure O O
to O O
indinavir B-Drug B-Drug
but O O
it O O
is O O
unclear O O
how O O
soon O O
after O O
didanosine B-Drug B-Drug
administration O O
indinavir B-Drug B-Drug
may O O
be O O
given O O
safely O O
. O O

In O O
our O O
laboratory O O
preliminary O O
whole O O
- O O
cell O O
tight O O
seal O O
recordings O O
of O O
rat O O
spinal O O
substantia O O
gelatinosa O O
neurons O O
including O O
biocytin O O
in O O
the O O
patch O O
pipette O O
yielded O O
a O O
significantly O O
smaller O O
proportion O O
of O O
neurons O O
hyperpolarized O O
by O O
selective B-Group O
opioid I-Group O
agonists I-Group O
compared O O
with O O
recordings O O
without O O
biocytin O O
. O O

aeruginosa O O
strains O O
isolated O O
from O O
various O O
hospitals O O
were O O
tested O O
for O O
their O O
resistances O O
against O O
many O O
antibiotics B-Group O
most O O
of O O
which O O
are O O
applied O O
in O O
the O O
treatment O O
of O O
P O O
. O O

When O O
taken O O
concurrently O O
with O O
ethanol B-Drug B-Drug
a O O
pharmacological O O
interaction O O
may O O
occur O O
potentiating O O
the O O
central O O
nervous O O
system O O
depression O O
produced O O
by O O
either O O
drug O O
. O O

The O O
clearance O O
by O O
means O O
of O O
9 B-Drug_n B-Drug_n
- O O
hydroxytolbutamide B-Drug_n B-Drug_n
and O O
carboxytolbutamide B-Drug_n B-Drug
was O O
significantly O O
reduced O O
in O O
both O O
groups O O
( O O
ie O O
from O O
9 O O
mL O O
/ O O
h O O
to O O
9 O O
mL O O
/ O O
h O O
in O O
the O O
group O O
that O O
received O O
9 O O
mg O O
of O O
tolbutamide B-Drug B-Drug
per O O
day O O
and O O
from O O
9 O O
mL O O
/ O O
h O O
to O O
9 O O
mL O O
/ O O
h O O
in O O
the O O
group O O
that O O
received O O
9 O O
mg O O
of O O
tolbutamide B-Drug B-Drug
per O O
day O O
) O O
. O O

A O O
muscle O O
biopsy O O
revealed O O
necrotizing O O
myopathy O O
secondary O O
to O O
a O O
toxin O O
. O O

Combined O O
treatment O O
with O O
9 B-Drug B-Group
9 I-Drug I-Group
( O O
OH B-Drug B-Drug
) O O
9D9 B-Drug B-Drug
and O O
TAM B-Drug_n B-Drug
enhances O O
the O O
degree O O
of O O
apoptosis O O
assessed O O
using O O
morphological O O
markers O O
that O O
identify O O
chromatin O O
and O O
nuclear O O
matrix O O
protein O O
condensation O O
. O O

9 O O
hour O O
after O O
starting O O
the O O
oxycodone B-Drug B-Drug
or O O
levofloxacin B-Drug B-Drug
9 O O
mg O O
p.o O O
. O O

In O O
vitro O O
activity O O
of O O
minocycline B-Drug B-Drug
combined O O
with O O
fosfomycin B-Drug B-Drug
against O O
clinical O O
isolates O O
of O O
methicillin B-Drug B-Drug
- O O
resistant O O
Staphylococcus O O
aureus O O
. O O

the O O
remainder O O
were O O
of O O
uncertain O O
cause O O
. O O

Jacalin B-Drug_n B-Drug
is O O
a O O
D O B-Drug_n
- O O
Gal O O
binding O O
lectin O O
and O O
should O O
be O O
a O O
useful O O
tool O O
for O O
studying O O
of O O
serum O O
and O O
secretory O O
IgA O O
. O O

9 O O
mg O O
result O O
in O O
incomplete O O
depletion O O
which O O
becomes O O
complete O O
after O O
a O O
second O O
additional O O
dose O O
. O O

Rhabdomyolysis O O
secondary O O
to O O
a O O
drug O O
interaction O O
between O O
simvastatin B-Drug B-Drug
and O O
clarithromycin B-Drug B-Drug
. O O

ulcerans O O
infection O O
. O O

CONCLUSIONS O O
: O O
Macrolide B-Group B-Group
antibiotics I-Group I-Group
inhibit O O
the O O
metabolism O O
of O O
HMG B-Group B-Drug_n
- O O
CoA B-Group B-Group
reductase I-Group I-Group
inhibitors I-Group I-Group
that O O
are O O
metabolized O O
by O O
CYP9A9 O O
( O O
i.e. O O
atorvastatin B-Drug B-Group
cerivastatin B-Drug I-Group
lovastatin B-Drug B-Drug
simvastatin B-Drug B-Drug
) O O
. O O

Chapter O O
9 O O
considers O O
the O O
mode O O
of O O
action O O
including O O
ovulation O O
prevention O O
; O O

and O O
glutamate B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
e.w O O
. O O
) O O

Interaction O O
of O O
celecoxib B-Drug B-Drug
with O O
different O O
anti B-Group O
- O O
cancer B-Group O
drugs I-Group O
is O O
antagonistic O O
in O O
breast O O
but O O
not O O
in O O
other O O
cancer O O
cells O O
. O O

OBJECTIVES O O
. O O

Primary O O
and O O
secondary O O
magnesium B-Drug B-Drug
deficiencies O O
constitute O O
the O O
sole O O
indication O O
of O O
physiological O O
oral O O
magnesium B-Drug B-Drug
therapy O O
. O O

aeruginosa O O
serotype O O
O9 O O
strains O O
but O O
not O O
S O O
. O O

Antitumor O O
effects O O
of O O
CRM9 B-Drug_n B-Drug_n
a O O
specific O O
inhibitor O O
of O O
HB O O
- O O
EGF O O
in O O
T O O
- O O
cell O O
acute O O
lymphoblastic O O
leukemia O O
. O O

Intermediate O O
doses O O
of O O
( O O
+ B-Drug_n O
) O O
- O O
NANM B-Drug_n B-Drug_n
or O O
PCP B-Drug_n B-Drug_n
produced O O
transient O O
increases O O
in O O
FI O O
responding O O
in O O
monkeys O O
and O O
sustained O O
increases O O
in O O
FI O O
responding O O
in O O
pigeons O O
; O O

Effect O O
of O O
ginsenosides B-Drug_n B-Drug
on O O
voltage O O
- O O
dependent O O
Ca O O
( O O
9+ O O
) O O
channel O O
subtypes O O
in O O
bovine O O
chromaffin O O
cells O O
. O O

antinociception O O
was O O
assessed O O
with O O
hot O O
- O O
plate O O
test O O
and O O
the O O
locomotor O O
exploratory O O
activities O O
were O O
assessed O O
with O O
holed O O
open O O
field O O
test O O
. O O

This O O
study O O
demonstrated O O
that O O
the O O
potent O O
cytochrome O O
P9 O O
enzyme O O
- O O
inducer O O
phenytoin B-Drug B-Drug
did O O
indeed O O
have O O
a O O
marked O O
effect O O
on O O
the O O
metabolism O O
of O O
quetiapine B-Drug B-Drug
resulting O O
in O O
a O O
9 O O
- O O
fold O O
increase O O
in O O
clearance O O
when O O
administered O O
concomitantly O O
to O O
patients O O
with O O
DSM O B-Drug_n
- O O
IV O B-Drug_n
- O O
diagnosed O O
schizophrenia O O
schizoaffective O O
disorder O O
or O O
bipolar O O
disorder O O
. O O

These O O
data O O
suggest O O
that O O
ginsenosides B-Drug_n B-Drug
are O O
negatively O O
coupled O O
to O O
three O O
types O O
of O O
calcium O B-Drug
channels O O
in O O
bovine O O
chromaffin O O
cell O O
including O O
an O O
omega B-Drug_n B-Drug
- O O
conotoxin B-Drug_n B-Drug_n
GVIA I-Drug_n I-Drug_n
- O O
sensitive O O
( O O
N O O
- O O
type O O
) O O
channel O B-Drug_n
an O O
omega B-Drug_n B-Drug_n
- O O
agatoxin B-Drug_n B-Drug_n
IVA I-Drug_n I-Drug_n
- O O
sensitive O O
( O O
P O O
- O O
type O O
) O O
channel O O
and O O
nimodipine B-Drug B-Drug
/ O O
omega B-Drug_n B-Drug
- O O
conotoxin B-Drug_n B-Drug
GVIA I-Drug_n I-Drug
/ O O
omega B-Drug_n B-Drug
- O O
agatoxin B-Drug_n B-Drug_n
VIA I-Drug_n I-Drug_n
- O O
resistant O O
( O O
presumptive O O
Q O O
- O O
type O O
) O O
channel O O
. O O

It O O
is O O
extensively O O
metabolized O O
predominantly O O
by O O
cytochrome O O
P9 O O
9A9 O O
. O O

9 O O
. O O

9 B-Drug O
9 I-Drug O
- O O
Dihydroxycholecalciferol B-Drug B-Drug_n
D9 I-Drug I-Drug_n
( O O
9 B-Drug O
9 I-Drug O
( O O
OH B-Drug B-Drug
) O O
9D9 B-Drug O
) O O
the O O
active O O
metabolite O O
of O O
vitamin B-Drug B-Drug
D I-Drug I-Drug
is O O
a O O
potent O O
inhibitor O O
of O O
breast O O
cancer O O
cell O O
growth O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

This O O
study O O
indicates O O
that O O
: O O
( O O
a O O
) O O
the O O
maximal O O
effects O O
of O O
resveratrol B-Drug_n B-Drug
on O O
resistance O O
arteries O O
from O O
lean O O
and O O
dietary O O
- O O
obese O O
rats O O
are O O
not O O
effected O O
by O O
endothelial O O
dysfunction O O
and O O
( O O
b O O
) O O
the O O
effects O O
of O O
resveratrol B-Drug_n B-Drug
in O O
lean O O
animals O O
( O O
where O O
endothelial O O
function O O
is O O
not O O
impaired O O
) O O
but O O
not O O
in O O
dietary O O
- O O
obese O O
rats O O
are O O
mediated O O
via O O
NO O O
. O O

Both O O
ibogaine B-Drug_n B-Drug_n
and O O
9 B-Drug_n B-Drug_n
- O O
MC B-Drug_n B-Drug_n
block O O
morphine B-Drug B-Drug
- O O
induced O O
and O O
nicotine B-Drug B-Drug
- O O
induced O O
dopamine O O
release O O
in O O
the O O
nucleus O O
accumbens O O
; O O

The O O
rats O O
treated O O
with O O
the O O
highest O O
dose O O
of O O
TML B-Drug_n O
manifested O O
significantly O O
longer O O
latencies O O
to O O
lose O O
the O O
righting O O
reflex O O
and O O
shorter O O
durations O O
of O O
sleep O O
than O O
did O O
controls O O
. O O

AAV9 B-Drug_n B-Drug
containing O O
cDNA O O
encoding O O
enhanced O O
green O O
fluorescent O O
protein O O
( O O
GFP O O
) O O
under O O
the O O
control O O
of O O
a O O
chicken O O
- O O
actin O O
promoter O O
was O O
delivered O O
by O O
intravitreal O O
injection O O
to O O
adult O O
mice O O
in O O
conjunction O O
with O O
enzymes O O
including O O
collagenase B-Drug_n B-Group
hyaluronan B-Drug_n I-Group
lyase I-Drug_n I-Group
heparinase B-Drug_n I-Group
III I-Drug_n I-Group
or O O
chondroitin B-Drug_n B-Group
ABC I-Drug_n I-Group
lyase I-Drug_n I-Group
. O O

Injection O O
of O O
estradiol B-Drug B-Drug
9 O O
min O O
before O O
a O O
nonlethal O O
dose O O
of O O
endotoxin B-Drug_n O
changed O O
the O O
serum O O
sex O O
steroid O O
hormone O O
response O O
of O O
male O O
rats O O
to O O
endotoxin B-Drug_n O
. O O

Pretreatment O O
of O O
rats O O
with O O
allopurinol B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
ip O O
) O O
or O O
Vitamin B-Drug B-Drug
E I-Drug I-Drug
( O O
9 O O
mg O O
/ O O
kg O O
per O O
day O O
ig O O
for O O
9 O O
days O O
and O O
a O O
dose O O
of O O
9 O O
mg O O
/ O O
kg O O
on O O
the O O
9th O O
day O O
) O O
provided O O
significant O O
protection O O
against O O
the O O
elevation O O
of O O
TBARS O O
levels O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
induced O O
by O O
single O O
high O O
dose O O
of O O
oral O O
cypermethrin B-Drug B-Drug
administration O O
within O O
9 O O
h O O
. O O

This O O
cluster O O
of O O
metabolic O O
abnormalities O O
has O O
been O O
termed O O
the O O
insulin O O
resistance O O
or O O
cardiovascular O O
dysmetabolic O O
syndrome O O
. O O

Amprenavir B-Drug B-Drug
inhibits O O
the O O
ERMBT O O
and O O
rifampin B-Drug B-Drug
and O O
rifabutin B-Drug B-Drug
are O O
equipotent O O
inducers O O
of O O
the O O
ERMBT O O
. O O

Some O O
preliminary O O
data O O
suggest O O
that O O
calcium B-Group B-Group
blockers I-Group I-Group
also O O
increase O O
generation O O
of O O
vasodilator O O
and O O
platelet O O
antiaggregant O O
prostacyclin O B-Drug
which O O
could O O
contribute O O
to O O
decrease O O
in O O
platelet O O
function O O
. O O

Furthermore O O
we O O
present O O
a O O
case O O
report O O
in O O
which O O
a O O
second O O
Herceptin B-Brand B-Drug
treatment O O
following O O
lapatinib B-Drug B-Drug
resulted O O
in O O
the O O
marked O O
shrinkage O O
of O O
multiple O O
metastatic O O
tumors O O
in O O
HER9 O O
- O O
positive O O
breast O O
cancer O O
. O O

In O O
some O O
synergistic O O
combinations O O
celecoxib O B-Drug
- O O
induced O O
abrogation O O
of O O
G9 O O
/ O O
M O O
arrest O O
was O O
not O O
associated O O
with O O
apoptosis O O
but O O
permanent O O
arrest O O
in O O
G9 O O
phase O O
. O O

bone O O
density O O
; O O

Chapter O O
9 O O
focuses O O
on O O
metabolic O O
effects O O
specifically O O
lipid O O
metabolism O O
carbohydrate O O
metabolism O O
and O O
diabetes O O
coagulation O O
factors O O
and O O
blood O O
pressure O O
. O O

Interaction O O
of O O
gentamycin B-Drug B-Drug
and O O
atracurium B-Drug B-Drug
in O O
anaesthetised O O
horses O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
In O O
December O O
9 O O
the O O
following O O
was O O
gathered O O
for O O
every O O
MAC O O
with O O
more O O
than O O
one O O
drug O O
treatment O O
: O O
age O O
sex O O
number O O
of O O
drugs O O
intrinsic O O
value O O
drugs O O
prescribed O O
daily O O
dose O O
and O O
pharmacological O O
interactions O O
( O O
PI O O
) O O
classified O O
( O O
using O O
the O O
scale O O
of O O
Hansten O O
9 O O
) O O
into O O
light O O
and O O
clinically O O
relevant O O
. O O

The O O
preclinical O O
combination O O
of O O
lenalidomide B-Drug B-Drug
with O O
the O O
mTOR O O
inhibitor O O
CCI B-Drug B-Drug
- O O
9 B-Drug O
has O O
displayed O O
synergy O O
in O O
vitro O O
and O O
represents O O
a O O
novel O O
combination O O
in O O
MM O O
. O O

About O O
three O O
weeks O O
prior O O
to O O
admission O O
the O O
patient O O
was O O
started O O
on O O
clarithromycin B-Drug B-Drug
for O O
sinusitis O O
. O O

9 B-Drug_n B-Drug_n
- O O
MC B-Drug_n B-Drug_n
does O O
not O O
produce O O
these O O
effects O O
. O O

These O O
results O O
suggest O O
that O O
D9 O O
receptors O O
are O O
coupled O O
to O O
activation O O
of O O
arc O O
gene O O
which O O
may O O
be O O
involved O O
in O O
functional O O
or O O
structural O O
alterations O O
underlying O O
neural O O
plasticity O O
triggered O O
by O O
METH B-Drug B-Drug
. O O

More O O
specific O O
applications O O
of O O
the O O
assay O O
of O O
thio O O
compounds O O
in O O
urine O O
allow O O
development O O
of O O
selective O O
methods O O
that O O
may O O
be O O
useful O O
for O O
biological O O
monitoring O O
. O O

In O O
spite O O
of O O
the O O
absence O O
of O O
kidney O O
function O O
the O O
value O O
of O O
the O O
elimination O O
rate O O
constant O O
was O O
significantly O O
decreased O O
in O O
the O O
presence O O
of O O
probenecid B-Drug B-Drug
( O O
from O O
9 O O
to O O
9 O O
/ O O
h O O
) O O
. O O

Spermine B-Drug B-Drug
and O O
to O O
a O O
lesser O O
extent O O
spermidine B-Drug_n O
enhanced O O
the O O
translocating O O
action O O
of O O
oleate O O
and O O
increased O O
its O O
effectiveness O O
in O O
transferring O O
the O O
phosphohydrolase O O
from O O
the O O
soluble O O
to O O
the O O
microsomal O O
fraction O O
. O O

The O O
last O O
9 O O
chapters O O
cover O O
interactions O O
with O O
drugs O O
and O O
laboratory O O
tests O O
common O O
side O O
effects O O
breast O O
feeding O O
and O O
effective O O
use O O
of O O
POCs B-Group O
. O O

Pharmacokinetic O O
Interaction O O
between O O
amprenavir B-Drug B-Drug
and O O
rifabutin B-Drug B-Drug
or O O
rifampin B-Drug B-Drug
in O O
healthy O O
males O O
. O O

RESULTS O O
. O O

These O O
data O O
suggest O O
the O O
modified O O
histidine O O
residues O O
on O O
toxin B-Drug_n B-Drug_n
A I-Drug_n I-Drug_n
are O O
critical O O
to O O
its O O
cytotoxic O O
activity O O
. O O

Warfarin B-Drug B-Drug
users O O
who O O
initiated O O
citalopram B-Drug O
fluoxetine B-Drug B-Drug
paroxetine B-Drug B-Drug
amitriptyline B-Drug I-Drug
or O O
mirtazapine B-Drug B-Drug
had O O
an O O
increased O O
risk O O
of O O
hospitalization O O
for O O
gastrointestinal O O
bleeding O O
. O O

Ibogaine B-Drug_n B-Drug
attenuates O O
but O O
9 B-Drug_n O
- O O
MC B-Drug_n B-Drug_n
potentiates O O
the O O
acute O O
locomotor O O
effects O O
of O O
morphine B-Drug B-Drug
; O O

Treatment O O
of O O
RAS O O
- O O
9T9 O O
cells O O
with O O
nucleophosmin O O
/ O O
B9 O O
antisense O O
oligomer O O
significantly O O
potentiated O O
the O O
apoptosis O O
induced O O
by O O
serum O O
deprivation O O
. O O

BACKGROUND O O
. O O

Conversely O O
at O O
exposure O O
levels O O
close O O
to O O
the O O
`` O O
limit O O
values O O
'' O O

Benzodiazepines B-Group O
were O O
administered O O
to O O
mice O O
9 O O
min O O
before O O
applying O O
the O O
analgesic B-Group B-Group
drugs I-Group I-Group
. O O

These O O
usually O O
clear O O
within O O
a O O
week O O
leaving O O
only O O
the O O
`` O O
drug O O
hunger O O
'' O O

Other O O
studies O O
with O O
a O O
lower O O
level O O
of O O
evidence O O
were O O
less O O
convincing O O
. O O

Atropine B-Drug B-Drug
either O O
alone O O
or O O
in O O
combination O O
with O O
alcohol B-Drug B-Drug
produced O O
approximately O O
the O O
same O O
degree O O
of O O
enhancement O O
of O O
component O O
P9 O O
. O O

In O O
some O O
lines O O
it O O
abrogates O O
the O O
drug O O
- O O
induced O O
G9 O O
/ O O
M O O
arrest O O
enhancing O O
pre O O
- O O
mature O O
entry O O
into O O
mitosis O O
with O O
damaged O O
DNA O O
thus O O
increasing O O
apoptosis O O
and O O
resulting O O
in O O
synergism O O
. O O

Piperine B-Drug_n B-Drug
( O O
CAS O B-Drug_n
9 O I-Drug_n
- O O
9 O B-Drug_n
- O O
9 O O
) O O
an O O
alkaloid O O
obtained O O
from O O
Piper O O
nigrum O O
and O O
P O O
. O O

In O O
seven O O
experiments O O
reactions O O
to O O
norepinephrine B-Drug O
and O O
oxytocin B-Drug B-Drug
were O O
PGF9alpha B-Drug B-Drug
. O O

In O O
contrast O O
to O O
its O O
enantiomer O O
( B-Drug_n O
- O O
) B-Drug_n O
- O O
NANM B-Drug_n B-Drug_n
failed O O
to O O
increase O O
FI O O
responding O O
significantly O O
in O O
either O O
species O O
; O O

Tumors O O
of O O
more O O
malignant O O
phenotype O O
were O O
demonstrated O O
only O O
in O O
genetically O O
predisposed O O
mice O O
( O O
C9BL O O
/ O O
9N O O
X O O
C9H O O
/ O O
HeN O O
F9 O O
) O O
that O O
received O O
one O O
dose O O
of O O
carcinogen O O
. O O

There O O
were O O
no O O
differences O O
between O O
cecectomized O O
and O O
control O O
rats O O
in O O
basal O O
small O O
intestinal O O
transits O O
or O O
in O O
dmPGE9 B-Drug_n B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
p.o O O
. O O
) O O
- O O
induced O O
enhancements O O
. O O

Molecular O O
basis O O
for O O
the O O
selective O O
toxicity O O
of O O
amphotericin B-Drug B-Drug
B I-Drug I-Drug
for O O
yeast O O
and O O
filipin B-Drug_n O
for O O
animal O O
cells O O
. O O

NSCLC O O
cell O O
lines O O
with O O
EGFR O O
T9M O O
mutation O O
and O O
K O O
- O O
ras O O
mutation O O
were O O
exposed O O
to O O
either O O
sunitinib B-Drug B-Drug
or O O
docetaxel B-Drug B-Drug
or O O
both O O
based O O
on O O
various O O
sequential O O
administrations O O
. O O

The O O
sensitivity O O
cell O O
cycle O O
apoptosis O O
and O O
DNA O O
damage O O
of O O
five O O
different O O
cancer O O
cell O O
lines O O
( O O
HeLa O O
HCT9 O O
HepG9 O O
MCF9 O O
and O O
U9 O O
) O O
to O O
9 B-Drug O
- O O
FU B-Drug O
cisplatin B-Drug B-Drug
doxorubicin B-Drug B-Drug
and O O
etoposide B-Drug O
celecoxib B-Drug B-Drug
following O O
different O O
incubation O O
schedules O O
were O O
analyzed O O
. O O

Emergence O O
agitation O O
( O O
EA O O
) O O
can O O
be O O
a O O
distressing O O
side O O
effect O O
of O O
pediatric O O
anesthesia O O
. O O

descending O O
epsilon O O
and O O
mu O O
systems O O
for O O
beta B-Drug_n B-Drug
- O O
endorphin B-Drug_n B-Drug
and O O
morphine B-Drug B-Drug
respectively O O
are O O
proposed O O
. O O

Blood O O
samples O O
were O O
drawn O O
at O O
9 O O
9 O O
9 O O
9 O O
9 O O
9 O O
9 O O
9 O O
9 O O
9 O O
9 O O
and O O
9 O O
hours O O
for O O
Cmax O O
tmax O O
and O O
AUC O O
determinations O O
. O O

There O O
was O O
evidence O O
for O O
longitudinal O O
stability O O
in O O
AUC O O
of O O
everolimus B-Drug B-Drug
during O O
the O O
course O O
of O O
the O O
study O O
. O O

Information O O
on O O
precautions O O
and O O
contraindications O O
indications O O
use O O
instructions O O
and O O
instructions O O
for O O
appropriate O O
actions O O
after O O
missing O O
a O O
pill O O
is O O
appended O O
. O O

Acute O O
dosing O O
with O O
clozapine B-Drug B-Drug
failed O O
to O O
alter O O
the O O
behavioral O O
effects O O
of O O
PCP B-Drug_n B-Drug_n
in O O
either O O
procedure O O
even O O
when O O
tested O O
up O O
to O O
doses O O
that O O
produced O O
pharmacological O O
effects O O
alone O O
. O O

There O O
are O O
a O O
number O O
of O O
steps O O
physicians O O
can O O
take O O
to O O
ensure O O
that O O
their O O
patients O O
are O O
not O O
being O O
undertreated O O
. O O

Clinical O O
implications O O
of O O
warfarin B-Drug B-Drug
interactions O O
with O O
five O O
sedatives B-Group O
. O O

The O O
concomitant O O
administration O O
of O O
either O O
cocaine B-Drug B-Drug
or O O
amphetamine B-Drug B-Drug
compounds O O
which O O
inhibit O O
neuronal O O
reuptake O O
of O O
norepinephrine O O
disrupts O O
the O O
behavioral O O
response O O
of O O
the O O
genetically O O
nervous O O
E O O
- O O
strain O O
subjects O O
to O O
a O O
far O O
greater O O
extent O O
than O O
the O O
stable O O
A O O
- O O
strain O O
subjects O O
. O O

Ticlopidine B-Drug B-Drug
treatment O O
increased O O
the O O
mean O O
area O O
under O O
the O O
plasma O O
concentration O O
- O O
time O O
curve O O
extrapolated O O
to O O
infinity O O
( O O
AUC O O
( O O
9 O O
- O O
) O O
) O O
of O O
oral O O
ketamine B-Drug B-Drug
by O O
9 O O
- O O
fold O O
whereas O O
itraconazole B-Drug B-Drug
treatment O O
did O O
not O O
increase O O
the O O
exposure O O
to O O
S B-Drug B-Drug
- O O
ketamine B-Drug B-Drug
. O O

amphotericin B-Drug B-Drug
B I-Drug I-Drug
however O O
is O O
useful O O
in O O
therapy O O
of O O
human O O
fungal O O
infections O O
because O O
it O O
is O O
less O O
toxic O O
. O O

On O O
the O O
contrary O O
neurotensin B-Drug_n B-Drug
and O O
tuftsin B-Drug_n B-Drug
were O O
agonists O O
in O O
induction O O
of O O
analgesia O O
. O O

Rifampin B-Drug B-Drug
markedly O O
increases O O
the O O
metabolic O O
clearance O O
of O O
amprenavir B-Drug B-Drug
and O O
coadministration O O
is O O
contraindicated O O
. O O

Stereoselective O O
behavioral O O
effects O O
of O O
N B-Drug_n B-Drug_n
- O O
allylnormetazocine B-Drug_n B-Drug
in O O
pigeons O O
and O O
squirrel O O
monkeys O O
. O O

The O O
authors O O
investigated O O
the O O
possibility O O
of O O
a O O
similar O O
interaction O O
between O O
oxycodone B-Drug B-Drug
and O O
levofloxacin B-Drug B-Drug
. O O

The O O
first O O
phase O O
of O O
this O O
sequence O O
initiation O O
is O O
considered O O
to O O
result O O
from O O
at O O
least O O
one O O
event O O
in O O
the O O
genetic O O
apparatus O O
. O O

Effect O O
of O O
diazepam B-Drug B-Drug
and O O
midazolam B-Drug B-Drug
on O O
the O O
antinociceptive O O
effect O O
of O O
morphine B-Drug B-Drug
metamizol B-Drug B-Drug
and O O
indomethacin B-Drug B-Drug
in O O
mice O O
. O O

This O O
problem O O
has O O
been O O
analysed O O
using O O
two O O
different O O
tasks O O
in O O
mice O O
: O O
a O O
bar O O
- O O
press O O
conditioning O O
and O O
a O O
spatial O O
discrimination O O
task O O
. O O

Drug O O
interaction O O
of O O
thyroxine B-Drug O
with O O
simeticone B-Drug B-Drug
has O O
not O O
been O O
reported O O
previously O O
and O O
is O O
not O O
listed O O
in O O
the O O
British O O
National O O
Formulary O O
for O O
Children O O
. O O

The O O
behavioral O O
effects O O
of O O
these O O
two O O
drugs O O
differ O O
and O O
they O O
do O O
not O O
act O O
on O O
the O O
same O O
target O O
sites O O
in O O
the O O
brain O O
although O O
they O O
may O O
share O O
or O O
partly O O
share O O
certain O O
properties O O
. O O

whereas O O
urinary O O
excretion O O
was O O
decreased O O
in O O
both O O
cases O O
. O O

DISCUSSION O O
: O O
Clarithromycin B-Drug B-Drug
is O O
a O O
potent O O
inhibitor O O
of O O
CYP9A9 O O
the O O
major O O
enzyme O O
responsible O O
for O O
simvastatin B-Drug B-Drug
metabolism O O
. O O

The O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
dimethylprostaglandin B-Drug_n B-Drug_n
E9 I-Drug_n I-Drug_n
( O O
dmPGE9 B-Drug_n B-Drug_n
) O O
- O O
induced O O
diarrhea O O
was O O
analyzed O O
in O O
cecectomized O O
rats O O
prepared O O
by O O
resecting O O
the O O
cecum O O
and O O
its O O
vasculature O O
without O O
disturbing O O
the O O
ileocecal O O
junction O O
. O O

Several O O
beta O O
- O O
adrenergic O O
neuroeffector O O
defects O O
occur O O
in O O
heart O O
failure O O
. O O

The O O
neurochemical O O
and O O
functional O O
consequences O O
following O O
MPTP B-Drug_n B-Drug
administration O O
to O O
the O O
rat O O
were O O
evaluated O O
and O O
compared O O
to O O
similar O O
effects O O
following O O
methamphetamine B-Drug B-Drug
administration O O
. O O

Altered O O
mental O O
status O O
in O O
an O O
adolescent O O
presents O O
a O O
diagnostic O O
challenge O O
and O O
the O O
clinician O O
depends O O
on O O
clinical O O
evaluation O O
and O O
laboratory O O
studies O O
to O O
determine O O
therapy O O
and O O
prognosis O O
. O O

A O O
reduction O O
in O O
PTH O O
level O O
of O O
greater O O
than O O
9 O O
% O O
was O O
experienced O O
by O O
9 O O
% O O
( O O
9 O O
/ O O
9 O O
) O O
of O O
our O O
cohort O O
. O O

No O O
data O O
from O O
prospective O O
clinical O O
trials O O
currently O O
exist O O
comparing O O
the O O
9 O B-Group
approved O I-Group
agents O I-Group
( O O
efavirenz B-Drug B-Drug
nevirapine B-Drug B-Drug
or O O
delavirdine B-Drug B-Drug
) O O
. O O

Cisplatin B-Drug B-Drug
was O O
administered O O
over O O
the O O
last O O
two O O
hours O O
of O O
the O O
thiosulfate B-Drug B-Drug
infusion O O
. O O

Sildenafil B-Drug B-Drug
citrate I-Drug O
: O O
a O O
therapeutic O O
update O O
. O O

Lack O O
of O O
an O O
effect O O
of O O
azithromycin B-Drug B-Drug
on O O
the O O
disposition O O
of O O
zidovudine B-Drug B-Drug
and O O
dideoxyinosine B-Drug B-Drug
in O O
HIV O O
- O O
infected O O
patients O O
. O O

injection O O
of O O
phencyclidine B-Drug_n B-Drug
( O O
PCP B-Drug_n B-Drug_n
) O O
were O O
observed O O
by O O
measuring O O
locomotor O O
activity O O
and O O
stereotyped O O
behavior O O
. O O

These O O
behavioral O O
changes O O
may O O
be O O
related O O
with O O
the O O
negative O O
symptoms O O
of O O
schizophrenia O O
. O O

Concomitantly O O
given O O
thiazide B-Group O
diuretics I-Group O
did O O
not O O
interfere O O
with O O
the O O
absorption O O
of O O
a O O
tablet O O
of O O
digoxin B-Drug B-Drug
. O O

There O O
is O O
the O O
possibility O O
of O O
precipitating O O
anticonvulsant O O
drug O O
toxicity O O
. O O

Both O O
ibogaine B-Drug_n B-Drug_n
and O O
9 B-Drug_n B-Drug_n
- O O
MC B-Drug_n B-Drug_n
decrease O O
extracellular O O
levels O O
of O O
dopamine O O
in O O
the O O
nucleus O O
accumbens O O
but O O
only O O
ibogaine B-Drug_n O
increases O O
extracellular O O
levels O O
of O O
serotonin O O
in O O
the O O
nucleus O O
accumbens O O
. O O

Prothrombin O B-Drug
times O O
were O O
measured O O
four O O
times O O
weekly O O
during O O
five O O
long O O
- O O
term O O
experiments O O
. O O

The O O
effect O O
of O O
natural O O
and O O
synthetic O B-Group
galloyl O I-Group
esters O O
on O O
glucocorticoid O O
- O O
induced O O
gene O O
expression O O
was O O
evaluated O O
by O O
using O O
rat O O
fibroblast O O
9Y9 O O
cells O O
stably O O
transfected O O
with O O
a O O
luciferase O O
reporter O O
gene O O
under O O
the O O
transcriptional O O
regulation O O
of O O
the O O
mouse O O
mammary O O
tumor O O
virus O O
promoter B-Drug O
. O O

Effects O O
of O O
CYP O O
inhibitors O O
on O O
precocene B-Drug_n B-Drug_n
I I-Drug_n I-Drug_n
metabolism O O
and O O
toxicity O O
in O O
rat O O
liver O O
slices O O
. O O

In O O
contrast O O
the O O
potency O O
of O O
norepinephrine B-Drug O
was O O
increased O O
in O O
failing O O
hearts O O
( O O
New O O
York O O
Heart O O
Association O O
functional O O
class O O
IV O O
) O O
in O O
relation O O
to O O
the O O
concentrations O O
producing O O
9 O O
% O O
of O O
the O O
maximal O O
effect O O
( O O
EC9 O O
) O O
. O O

Previous O O
studies O O
have O O
demonstrated O O
that O O
sunitinib B-Drug B-Drug
has O O
the O O
anti O O
- O O
tumor O O
activity O O
in O O
human O O
non O O
- O O
small O O
cell O O
lung O O
cancer O O
( O O
NSCLC O O
) O O
. O O

Cancer O O
in O O
the O O
elderly O O
: O O
basic O O
science O O
and O O
clinical O O
aspects O O
. O O

Regulatory O O
agencies O O
state O O
that O O
the O O
combination O O
of O O
clopidogrel B-Drug B-Drug
and O O
the O O
CYP9C9 O B-Group
inhibitors O I-Group
omeprazole B-Drug B-Drug
and O O
esomeprazole B-Drug B-Drug
should O O
be O O
avoided O O
. O O

Careful O O
observations O O
on O O
hepatotoxicity O O
are O O
suggested O O
when O O
acetaminophen B-Drug B-Drug
is O O
prescribed O O
with O O
caffeine B-Drug B-Drug
. O O

Because O O
of O O
the O O
low O O
dietary O O
cobalt B-Drug B-Drug
concentration O O
as O O
compared O O
to O O
the O O
iron B-Drug O
contents O O
of O O
the O O
diets O O
no O O
effect O O
of O O
cobalt B-Drug B-Drug
on O O
iron B-Drug B-Drug
absorption O O
and O O
excretion O O
occurred O O
. O O

The O O
initiated O O
cells O O
that O O
result O O
from O O
this O O
hit O O
may O O
vary O O
from O O
those O O
that O O
demonstrate O O
very O O
little O O
progression O O
in O O
cell O O
type O O
and O O
may O O
or O O
may O O
not O O
require O O
exogenous O O
enhancement O O
of O O
growth O O
to O O
those O O
that O O
can O O
progress O O
very O O
rapidly O O
to O O
fully O O
malignant O O
behavior O O
. O O

The O O
clinical O O
presentation O O
and O O
natural O O
history O O
of O O
neoplasia O O
are O O
also O O
affected O O
by O O
aging O O
. O O

Thus O O
the O O
selective O O
regulation O O
of O O
voltage O O
- O O
dependent O O
Ca O O
( O O
9+ O O
) O O
subtypes O O
by O O
ginsenosides B-Drug_n B-Drug
in O O
bovine O O
chromaffin O O
cell O O
could O O
be O O
the O O
cellular O O
basis O O
of O O
antistress O O
effects O O
induced O O
by O O
ginseng B-Drug O
. O O

Responses O O
to O O
arginine B-Drug O
of O O
the O O
perfused O O
pancreas O O
of O O
the O O
genetically O O
diabetic O O
Chinese O O
hamster O O
. O O

The O O
relative O O
risk O O
of O O
myocardial O O
infarction O O
during O O
sexual O O
activity O O
is O O
not O O
significantly O O
higher O O
than O O
for O O
healthy O O
persons O O
. O O

Effect O O
of O O
estradiol B-Drug B-Drug
on O O
endotoxin B-Drug_n B-Drug_n
- O O
induced O O
changes O O
in O O
steroid O O
hormone O O
levels O O
and O O
lethality O O
in O O
male O O
rats O O
. O O

This O O
approach O O
combines O O
liquid O O
chromatography O O
mass O O
spectrometry O O
( O O
LC O O
MS O O
) O O
detection O O
methods O O
with O O
multiple O O
toxicity O O
endpoints O O
to O O
enable O O
identification O O
of O O
critical O O
metabolic O O
pathways O O
for O O
hepatotoxicity O O
. O O

Prostatic O O
epithelium O O
proliferates O O
in O O
a O O
defined O O
medium O O
consisting O O
of O O
basal O O
medium O O
RPMI9 O O
containing O O
transferrin B-Drug_n B-Drug
( O O
9 O O
microgram O O
/ O O
ml O O
) O O
EGF B-Drug_n O
( O O
9 O O
ng O O
/ O O
ml O O
) O O
and O O
insulin B-Drug B-Drug
( O O
9 O O
micrograms O O
/ O O
ml O O
or O O
9 O O
IU O O
/ O O
ml O O
) O O
. O O

The O O
effect O O
of O O
rifampin B-Drug B-Drug
on O O
the O O
warfarin B-Drug B-Drug
requirement O O
of O O
our O O
patient O O
appeared O O
to O O
be O O
maximal O O
9 O O
to O O
9 O O
days O O
after O O
the O O
initiation O O
of O O
rifampin B-Drug B-Drug
and O O
extended O O
a O O
similar O O
length O O
of O O
time O O
after O O
rifampin B-Drug B-Drug
withdrawal O O
. O O

Therapeutic O O
drug O O
monitoring O O
( O O
TDM O O
) O O
of O O
gentamicin B-Drug B-Drug
therapy O O
and O O
bone O O
scintigraphy O O
employing O O
9mTc B-Drug O
- O O
MDP B-Drug O
as O O
the O O
radiopharmaceutical B-Group O
was O O
carried O O
out O O
in O O
9 O O
patients O O
. O O

To O O
study O O
the O O
pancreatic O O
effects O O
of O O
other O O
agents O B-Group
dynamic O I-Group
insulin O I-Group
and O O
glucagon O O
release O O
was O O
measured O O
from O O
the O O
in O O
vitro O O
perfused O O
pancreases O O
of O O
normal O O
and O O
diabetic O O
Chinese O O
hamsters O O
in O O
response O O
to O O
various O O
combinations O O
of O O
arginine B-Drug B-Drug
( O O
9mM O O
) O O
glucose B-Drug B-Drug
( O O
9 O O
or O O
9 O O
mg. O O
per O O
9 O O
ml O O
. O O
) O O
and O O
theophylline B-Drug B-Drug
( O O
9 O O
mM O O
) O O
. O O

There O O
were O O
9 O O
PI O O
with O O
drugs O O
of O O
low O O
intrinsic O O
value O O
( O O
9 O O
% O O
; O O
9 O O
% O O
CI O O
+ O O
/ O O
- O O
9 O O
) O O
. O O

Measurement O O
of O O
nociception O O
was O O
performed O O
within O O
9 O O
h O O
after O O
benzodiazepine B-Group B-Drug
administration O O
. O O

Interaction O O
studies O O
have O O
been O O
performed O O
with O O
fluvastatin B-Drug B-Drug
and O O
several O O
drugs O O
with O O
which O O
it O O
might O O
be O O
coadministered O O
. O O

The O O
successive O O
application O O
of O O
glycine B-Drug B-Drug
( O O
9 O O
or O O
9 O O
mg O O
/ O O
kg O O
egg O O
weight O O
( O O
e.w O O
. O O
) O O
and O O
glutamate B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
e.w O O
. O O
) O O
in O O
a O O
9 O O
min O O
interval O O
significantly O O
increased O O
the O O
activation O O
of O O
spontaneous O O
motility O O
of O O
9 O O
- O O
day O O
- O O
old O O
chick O O
embryos O O
in O O
comparison O O
with O O
the O O
effect O O
of O O
glutamate B-Drug B-Drug
alone O O
. O O

If O O
taken O O
9 O O
hour O O
before O O
indinavir B-Drug B-Drug
( O O
IDV B-Drug O
) O O
didanosine B-Drug B-Drug
does O O
not O O
affect O O
IDV B-Drug O
exposure O O
despite O O
persistent O O
buffering O O
effects O O
. O O

These O O
observations O O
strongly O O
suggest O O
that O O
the O O
homodimeric O O
structure O O
of O O
contortrostatin B-Drug_n B-Drug
functionally O O
distinguishes O O
it O O
from O O
other O O
monomeric O O
members O O
of O O
the O O
disintegrin O O
family O O
. O O

Five O O
days O O
of O O
dofetilide B-Drug O
treatment O O
did O O
not O O
significantly O O
affect O O
steady O O
- O O
state O O
pharmacokinetic O O
variables O O
of O O
digoxin B-Drug B-Drug
compared O O
with O O
placebo O O
; O O

Electrophilic O B-Drug
agents O I-Drug
- O O
- O O
a O O
class O O
of O O
chemicals O O
that O O
includes O O
most O O
genotoxic O O
compounds O O
- O O
- O O
can O O
be O O
inactivated O B-Drug
by O O
reaction O O
with O O
glutathione O O
or O O
other O O
SH O O
- O O
bearing O O
molecules O O
. O O

Sertraline B-Drug B-Drug
neutralized O O
the O O
increase O O
of O O
glycemia O O
induced O O
by O O
oral O O
glucose B-Drug O
overload O O
. O O

Effect O O
of O O
coadministered O B-Group
drugs O I-Group
and O O
ethanol B-Drug B-Drug
on O O
the O O
binding O O
of O O
therapeutic O O
drugs O O
to O O
human O O
serum O O
in O O
vitro O O
. O O

Thirty O O
male O O
rats O O
of O O
the O O
Fischer O O
- O O
9 O O
strain O O
were O O
divided O O
into O O
three O O
equal O O
groups O O
and O O
were O O
given O O
injections O O
of O O
trimethyl B-Drug_n O
lead I-Drug_n O
( O O
TML B-Drug_n O
) O O
( O O
9 O O
or O O
9 O O
mg O O
/ O O
kg O O
/ O O
ml O O
SC O O
) O O
or O O
the O O
saline O O
vehicle O O
. O O

CONCLUSIONS O O
: O O
The O O
combination O O
of O O
CHOP O O
plus O O
HAART O O
is O O
feasible O O
and O O
may O O
reduce O O
the O O
morbidity O O
from O O
OIs O O
in O O
HIV O O
- O O
NHL O O
patients O O
. O O

The O O
impact O O
of O O
the O O
combined O O
chemotherapy O O
plus O O
HAART O O
treatment O O
on O O
patient O O
survival O O
needs O O
urgently O O
to O O
be O O
evaluated O O
in O O
prospective O O
studies O O
. O O

Although O O
verapamil B-Drug B-Drug
administered O O
at O O
either O O
dose O O
had O O
little O O
or O O
no O O
effect O O
on O O
the O O
enhancement O O
of O O
intestinal O O
carcinogenesis O O
by O O
bombesin B-Drug_n B-Drug
or O O
on O O
the O O
location O O
histologic O O
type O O
depth O O
of O O
involvement O O
labeling O O
index O O
apoptotic O O
index O O
or O O
tumor O O
vascularity O O
of O O
intestinal O O
cancers O O
it O O
significantly O O
decreased O O
the O O
incidence O O
of O O
cancer O O
metastasis O O
. O O

Synergism O O
was O O
observed O O
when O O
GL B-Drug_n B-Drug_n
was O O
combined O O
with O O
cefazolin B-Drug B-Drug
against O O
Bacillus O O
subtilis O O
and O O
Klebsiella O O
oxytoca O O
. O O

This O O
increased O O
incidence O O
of O O
atherosclerotic O O
disease O O
is O O
intricately O O
associated O O
with O O
insulin O O
resistance O O
which O O
is O O
a O O
major O O
pathophysiologic O O
abnormality O O
in O O
type O O
9 O O
diabetes O O
. O O

Ibogaine B-Drug_n B-Drug
but O O
not O O
9 B-Drug_n O
- O O
MC B-Drug_n B-Drug_n
decreases O O
heart O O
rate O O
at O O
high O O
doses O O
. O O

Dose O O
- O O
response O O
curves O O
( O O
derived O O
from O O
the O O
results O O
of O O
using O O
the O O
tablets O O
as O O
well O O
as O O
pure O O
powders O O
) O O
showed O O
that O O
tripelennamine B-Drug B-Drug
was O O
responsible O O
for O O
the O O
inhibitory O O
activity O O
which O O
was O O
partially O O
antagonized O O
by O O
pentazocine B-Drug B-Drug
. O O

No O O
interactions O O
have O O
been O O
observed O O
with O O
beta B-Group B-Group
- O O
receptor B-Group O
blockers I-Group B-Group
calcium B-Group I-Group
antagonists I-Group I-Group
thiazide B-Group I-Group
and O O
loop B-Group O
diuretics I-Group O
and O O
ACE B-Group O
inhibitors I-Group O
. O O

Increased O O
D O O
- O O
like O O
receptor O O
sensitivity O O
appears O O
to O O
have O O
enhanced O O
the O O
behavioral O O
effects O O
of O O
amphetamine B-Drug B-Drug
but O O
these O O
effects O O
were O O
more O O
prevalent O O
in O O
adolescent O O
female O O
rats O O
compared O O
with O O
male O O
rats O O
. O O

Depression O O
does O O
not O O
always O O
require O O
antidepressant B-Group B-Group
drug I-Group I-Group
therapy O O
and O O
antidepressants B-Group B-Group
have O O
no O O
proven O O
preventive O O
impact O O
on O O
hot O O
flushes O O
linked O O
to O O
the O O
menopause O O
. O O

The O O
role O O
of O O
norepinephrine B-Drug O
uptake O O
- O O
9 O O
was O O
studied O O
in O O
electrically O O
stimulated O O
( O O
9 O O
Hz O O
9 O O
degrees O O
C O O
) O O
human O O
ventricular O O
cardiac O O
preparations O O
and O O
isolated O O
myocardial O O
membranes O O
. O O

This O O
loss O O
of O O
microtubules O O
on O O
cooling O O
the O O
nerves O O
and O O
their O O
reappearance O O
on O O
rewarming O O
was O O
a O O
rapid O O
process O O
; O O

The O O
results O O
indicate O O
that O O
a O O
spinal O O
naloxone B-Drug B-Drug
- O O
sensitive O O
endorphinergic O O
system O O
is O O
involved O O
in O O
the O O
production O O
of O O
beta B-Drug_n B-Drug_n
- O O
endorphin B-Drug_n B-Drug_n
but O O
not O O
morphine B-Drug B-Drug
- O O
induced O O
tail O O
- O O
flick O O
inhibition O O
and O O
suggest O O
that O O
intraventricular O O
beta B-Drug_n B-Drug_n
- O O
endorphin B-Drug_n B-Drug_n
and O O
morphine B-Drug B-Drug
elicit O O
their O O
pharmacological O O
actions O O
via O O
the O O
activation O O
of O O
different O O
descending O O
pain O O
inhibitory O O
systems O O
; O O

Comparative O O
analysis O O
of O O
the O O
effects O O
of O O
stimulation O O
and O O
inhibition O O
of O O
cholino O O
- O O
and O O
adrenoreceptors O O
on O O
this O O
inhibitory O O
action O O
of O O
angiotensins B-Drug_n O
suggested O O
the O O
mediation O O
of O O
angiotensin B-Drug_n O
influence O O
through O O
the O O
modulation O O
of O O
cholinergic O O
reactions O O
of O O
parietal O O
cells O O
in O O
the O O
stomach O O
. O O

Interest O O
in O O
administering O O
compounds O O
in O O
combination O O
lies O O
both O O
in O O
enhancing O O
efficacious O O
effects O O
and O O
in O O
limiting O O
adverse O O
effects O O
. O O

The O O
interaction O O
was O O
studied O O
at O O
neutral O O
acidic O O
and O O
basic O O
conditions O O
both O O
at O O
room O O
temperature O O
and O O
9 O O
C O O
. O O

Evaluation O O
of O O
its O O
efficacy O O
and O O
toxicity O O
. O O

The O O
interface O O
between O O
bone O O
and O O
bone O O
marrow O O
in O O
uremia O O
represents O O
a O O
critical O O
step O O
in O O
red O O
blood O O
cell O O
production O O
which O O
merits O O
further O O
investigation O O
. O O

In O O
comparison O O
with O O
haloperidol B-Drug B-Drug
the O O
adverse O O
events O O
reported O O
significantly O O
more O O
frequently O O
with O O
olanzapine B-Drug B-Drug
in O O
> O O
or O O
= O O
9 O O
% O O
of O O
patients O O
were O O
dry O O
mouth O O
bodyweight O O
gain O O
and O O
increased O O
appetite O O
and O O
compared O O
with O O
risperidone B-Drug B-Drug
only O O
bodyweight O O
gain O O
occurred O O
significantly O O
more O O
frequently O O
with O O
olanzapine B-Drug B-Drug
. O O

Modification O O
of O O
toxin B-Drug_n B-Drug_n
A I-Drug_n I-Drug_n
with O O
diethyl B-Drug_n B-Group
pyrocarbonate I-Drug_n I-Group
abolished O O
both O O
its O O
cytotoxic O O
activity O O
and O O
the O O
ability O O
of O O
the O O
toxin O O
to O O
bind O O
Zn O O
- O O
Sepharose O O
gel O O
. O O

An O O
intravenous O O
dose O O
of O O
9 O O
mg O O
perchlorate B-Drug_n O
was O O
in O O
respect O O
of O O
competitive O O
suppression O O
of O O
organs O O
actively O O
concentrating O O
pertechnetate B-Drug O
as O O
effective O O
as O O
intravenous O O
9 O O
mg O O
ClO O O
- O O
9 O O
- O O
simultaneously O O
or O O
9 O O
mg O O
orally O O
9 O O
min O O
before O O
the O O
injection O O
of O O
radiopertechnetate B-Drug B-Drug
. O O

The O O
minimal O O
inhibitory O O
concentration O O
as O O
well O O
as O O
minimal O O
bactericidal O O
concentration O O
of O O
KRM B-Drug_n B-Drug_n
- O O
9 B-Drug_n O
against O O
M O O
. O O

The O O
addition O O
of O O
heparinase B-Drug_n B-Group
III I-Drug_n I-Group
or O O
chondroitin B-Drug_n B-Group
ABC I-Drug_n I-Group
lyase I-Drug_n I-Group
greatly O O
enhanced O O
transduction O O
of O O
the O O
retinal O O
ganglion O O
cell O O
layer O O
and O O
increased O O
the O O
depth O O
of O O
transduction O O
into O O
the O O
outer O O
retina O O
. O O

However O O
the O O
elevated O O
risk O O
with O O
mirtazapine B-Drug B-Drug
suggests O O
that O O
a O O
drug O O
- O O
drug O O
interaction O O
may O O
not O O
have O O
been O O
responsible O O
for O O
all O O
of O O
the O O
observed O O
increased O O
risk O O
. O O

Infusion O O
of O O
arginine B-Drug B-Drug
alone O O
markedly O O
decreased O O
the O O
amount O O
of O O
extractable O O
pancreatic O O
insulin O O
and O O
glucagon O O
. O O

Pharmacokinetic O O
interaction O O
between O O
single O O
oral O O
doses O O
of O O
diltiazem B-Drug B-Drug
and O O
sirolimus B-Drug B-Drug
in O O
healthy O O
volunteers O O
. O O

Similarly O O
diazepam B-Drug B-Drug
decreased O O
the O O
antinociceptive O O
effect O O
of O O
metamizol B-Drug B-Drug
( O O
only O O
in O O
the O O
tail O O
- O O
flick O O
test O O
) O O
and O O
indomethacin B-Drug B-Drug
. O O

The O O
findings O O
suggest O O
that O O
the O O
dosage O O
of O O
S B-Drug B-Drug
- O O
ketamine B-Drug B-Drug
should O O
be O O
reduced O O
in O O
patients O O
receiving O O
ticlopidine B-Drug B-Drug
. O O

Fluoxetine B-Drug B-Drug
and O O
moclobemide B-Drug O
increased O O
blood O O
glucose B-Drug O
at O O
different O O
times O O
after O O
the O O
glucose O O
overload O O
. O O

Because O O
of O O
the O O
pronounced O O
intersubject O O
variability O O
in O O
the O O
extent O O
of O O
the O O
sirolimus B-Drug B-Drug
- O O
diltiazem B-Drug B-Drug
interaction O O
whole O O
blood O O
sirolimus B-Drug B-Drug
concentrations O O
should O O
be O O
monitored O O
closely O O
in O O
patients O O
treated O O
with O O
the O O
two O O
drugs O O
. O O

Effect O O
of O O
probenecid B-Drug B-Drug
on O O
the O O
apparent O O
volume O O
of O O
distribution O O
and O O
elimination O O
of O O
cloxacillin B-Drug B-Drug
. O O

higher O O
doses O O
decreased O O
FI O O
and O O
FR O O
responding O O
in O O
both O O
species O O
. O O

In O O
addition O O
patients O O
taking O O
drugs O O
that O O
inhibit O O
the O O
cytochrome O O
P9 O O
9A9 O O
isozyme O O
which O O
metabolizes O O
sildenafil B-Drug B-Drug
may O O
experience O O
increased O O
drug O O
concentrations O O
and O O
possible O O
toxicity O O
from O O
normal O O
doses O O
of O O
sildenafil B-Drug B-Drug
. O O

Like O O
all O O
hormonal B-Group O
contraceptives I-Group O
certain O O
hepatic O O
enzyme O O
- O O
inducing O O
drugs O O
may O O
reduce O O
its O O
efficacy O O
. O O

On O O
the O O
basis O O
of O O
the O O
principles O O
observed O O
the O O
concentrations O O
fo O O
these O O
hormones O O
were O O
investigated O O
in O O
the O O
plasma O O
of O O
dogs O O
deprived O O
of O O
water O O
for O O
9 O O
days O O
and O O
then O O
allowed O O
to O O
drink O O
. O O

The O O
pathophysiologic O O
consequences O O
could O O
be O O
an O O
increased O O
synaptic O O
concentration O O
of O O
norepinephrine B-Drug O
predisposing O O
to O O
adenylyl O O
cyclase O O
desensitization O O
. O O

Each O O
serum O O
without O O
the O O
other O O
added O O
drug O O
as O O
well O O
as O O
the O O
serum O O
supplemented O O
with O O
the O O
other O O
drug O O
at O O
the O O
three O O
concentrations O O
was O O
dialyzed O O
against O O
phosphate O O
buffer O O
. O O

RESULTS O O
: O O
During O O
treatment O O
with O O
fluvoxamine B-Drug B-Drug
there O O
was O O
a O O
statistically O O
significant O O
decrease O O
in O O
the O O
median O O
of O O
the O O
total O O
clearance O O
of O O
tolbutamide B-Drug B-Drug
from O O
9 O O
mL O O
/ O O
h O O
to O O
9 O O
mL O O
/ O O
h O O
among O O
the O O
volunteers O O
who O O
received O O
9 O O
mg O O
/ O O
d O B-Drug
. O O

Interaction O O
of O O
dacarbazine B-Drug B-Drug
and O O
imexon B-Drug_n B-Drug
in O O
vitro O O
and O O
in O O
vivo O O
in O O
human O O
A9 O O
melanoma O O
cells O O
. O O

Collectively O O
these O O
findings O O
contribute O O
to O O
increase O O
our O O
knowledge O O
of O O
DEB O O
- O O
induce O O
toxicity O O
and O O
will O O
be O O
very O O
useful O O
when O O
applied O O
in O O
studies O O
with O O
lymphocytes O O
from O O
FA O O
patients O O
in O O
order O O
to O O
find O O
out O O
a O O
protective O O
agent O O
against O O
spontaneous O O
and O O
DEB O O
- O O
induced O O
chromosome O O
instability O O
. O O

therefore O O
the O O
use O O
of O O
dofetilide B-Drug B-Drug
does O O
not O O
necessitate O O
an O O
adjustment O O
in O O
digoxin B-Drug B-Drug
dose O O
to O O
maintain O O
therapeutic O O
digoxin O B-Drug
levels O O
. O O

Metal O O
mixture O O
toxicity O O
investigation O O
was O O
undertaken O O
with O O
equal O O
concentrations O O
of O O
the O O
metals O O
. O O

In O O
contrast O O
in O O
Ontario O O
alone O O
in O O
9 O O
and O O
9 O O
there O O
were O O
9 O O
deaths O O
in O O
amphetamine B-Drug B-Drug
users O O
of O O
which O O
9 O O
were O O
due O O
to O O
accident O O
suicide O O
or O O
homicide O O
. O O

Studies O O
on O O
two O O
strains O O
of O O
pointer O O
dogs O O
have O O
demonstrated O O
that O O
administration O O
of O O
a O O
benzodiazepine B-Group B-Drug
( O O
chlordiazepoxide B-Drug O
) O O
facilitates O O
acquisition O O
of O O
goal O O
- O O
directed O O
behavior O O
in O O
`` O O
genetically O O
nervous O O
'' O O

Although O O
neither O O
dexamethasone B-Drug B-Drug
nor O O
retinyl B-Drug B-Drug
acetate I-Drug I-Drug
affected O O
the O O
proliferation O O
of O O
prostatic O O
epithelium O O
in O O
RPMI9 O O
containing O O
transferrin B-Drug_n B-Drug
alone O O
they O O
modify O O
the O O
mitogenic O O
effect O O
of O O
EGF B-Drug_n O
and O O
insulin B-Drug O
. O O

Current O O
immunosuppressive O B-Group
therapies O I-Group
are O O
effective O O
but O O
can O O
be O O
associated O O
with O O
significant O O
adverse O O
reactions O O
. O O

9 B-Drug_n B-Drug_n
- O O
Methoxycoronaridine B-Drug_n B-Drug_n
( O O
9 B-Drug_n B-Drug_n
- O O
MC B-Drug_n B-Drug_n
) O O
and O O
ibogaine B-Drug_n O
: O O
comparison O O
of O O
antiaddictive O O
efficacy O O
toxicity O O
and O O
mechanisms O O
of O O
action O O
. O O

The O O
susceptibility O O
results O O
for O O
minocycline B-Drug B-Drug
and O O
fosfomycin B-Drug B-Drug
were O O
interpreted O O
according O O
to O O
the O O
most O O
relevant O O
criteria O O
. O O

These O O
results O O
suggest O O
that O O
exposure O O
to O O
environmental O O
lead B-Drug_n O
may O O
alter O O
the O O
biological O O
and O O
behavioral O O
responsiveness O O
of O O
an O O
animal O O
to O O
alcohol B-Drug B-Drug
. O O

To O O
determine O O
whether O O
injection O O
of O O
thiosulfate B-Drug B-Drug
would O O
permit O O
larger O O
doses O O
of O O
cisplatin B-Drug B-Drug
to O O
be O O
administered O O
a O O
fixed O O
9 O O
- O O
g O O
/ O O
m9 O O
dose O O
of O O
thiosulfate B-Drug B-Drug
was O O
given O O
intravenously O O
over O O
three O O
hours O O
concurrently O O
with O O
escalating O O
doses O O
of O O
cisplatin B-Drug B-Drug
. O O

Vancomycin O B-Drug
resistance O O
reversal O O
in O O
enterococci O O
by O O
flavonoids O O
. O O

Conjugation O O
at O O
NaCMC B-Drug_n B-Drug_n
with O O
cysteine B-Drug B-Drug
moieties O O
significantly O O
improves O O
the O O
intestinal O O
permeation O O
of O O
the O O
hydrophilic O O
molecule O O
NaFlu B-Drug B-Drug
and O O
the O O
model O O
peptide O O
drugs O O
bacitracin B-Drug B-Drug
and O O
insulin B-Drug O
in O O
vitro O O
therefore O O
this O O
conjugated O O
system O O
maybe O O
useful O O
for O O
peroral O O
administration O O
of O O
peptide O O
drugs O O
in O O
the O O
future O O
. O O

Twenty O O
- O O
four O O
h O O
exposures O O
of O O
fully O O
formed O O
cysts O O
had O O
no O O
effect O O
on O O
excystment O O
in O O
vitro O O
. O O

The O O
regulation O O
of O O
the O O
level O O
of O O
the O O
glucocorticoid O O
- O O
induced O O
gene O O
expression O O
by O O
the O O
antioxidative O O
gallates O O
is O O
of O O
great O O
interest O O
from O O
a O O
therapeutic O O
point O O
of O O
view O O
. O O

and O O
clinical O O
implications O O
. O O

The O O
effects O O
of O O
ketamine B-Drug B-Drug
and O O
of O O
Innovar B-Brand B-Group
anesthesia O I-Group
on O O
digitalis B-Group O
tolerance O O
in O O
dogs O O
. O O

Successful O O
prophylaxis O O
of O O
manic O O
- O O
depressive O O
disorder O O
requires O O
more O O
than O O
the O O
prescription O O
of O O
lithium B-Drug O
carbonate I-Drug O
. O O

The O O
effectiveness O O
of O O
norepinephrine B-Drug O
in O O
increasing O O
the O O
force O O
of O O
contraction O O
was O O
decreased O O
in O O
relation O O
to O O
the O O
degree O O
of O O
heart O O
failure O O
. O O

Fourteen O O
days O O
later O O
all O O
animals O O
were O O
challenged O O
with O O
a O O
single O O
hypnotic O O
dose O O
of O O
ethanol B-Drug B-Drug
( O O
9 O O
g O O
/ O O
kg O O
IP O O
) O O
. O O

All O O
antagonists O O
decreased O O
the O O
time O O
spent O O
in O O
the O O
light O O
zone O O
in O O
this O O
test O O
which O O
suggested O O
that O O
these O O
compounds O O
have O O
anxiogenic O O
effects O O
. O O

The O O
drug O O
interaction O O
between O O
warfarin B-Drug B-Drug
and O O
rifampin B-Drug B-Drug
is O O
not O O
well O O
known O O
. O O

METHODS O O
AND O O
AIMS O O
: O O
We O O
conducted O O
a O O
retrospective O O
cohort O O
study O O
of O O
9 O O
end O O
- O O
stage O O
renal O O
disease O O
( O O
ESRD O O
) O O
patients O O
( O O
age O O
: O O
9 O O
9 O O
; O O
mean O O
SD O O
; O O
9 O O
: O O
male O O
) O O
who O O
had O O
at O O
least O O
9 O O
months O O
of O O
cinacalcet B-Drug B-Drug
therapy O O
. O O

Furthermore O O
arsenate B-Drug_n B-Drug
and O O
phosphate B-Drug O
do O O
not O O
appear O O
to O O
share O O
a O O
common O O
transport O O
pathway O O
in O O
the O O
duodenum O O
and O O
no O O
evidence O O
was O O
obtained O O
for O O
any O O
interaction O O
between O O
the O O
two O O
at O O
this O O
level O O
. O O

There O O
were O O
no O O
clinically O O
significant O O
changes O O
in O O
corrected O O
QT O O
intervals O O
during O O
administration O O
of O O
cisapride B-Drug B-Drug
alone O O
or O O
with O O
fluoxetine B-Drug B-Drug
. O O

Close O O
monitoring O O
allows O O
physicians O O
to O O
minimize O O
risks O O
maximize O O
benefits O O
and O O
get O O
the O O
most O O
out O O
of O O
what O O
modern O O
medications O O
can O O
do O O
to O O
help O O
older O O
patients O O
. O O

Leukopenia O O
was O O
similar O O
between O O
the O O
two O O
groups O O
but O O
colony O O
stimulating O O
factor O O
support O O
was O O
significantly O O
greater O O
in O O
the O O
CHOP O O
- O O
HAART O O
group O O
than O O
in O O
the O O
control O O
group O O
( O O
9 O O
% O O
vs. O O
9 O O
% O O
respectively O O
; O O
P O O
= O O
9 O O
) O O
. O O

[ O O
A O O
pharmacological O O
analysis O O
of O O
the O O
effect O O
of O O
angiotensin B-Drug_n O
on O O
stimulated O O
gastric O O
secretion O O
] O O
Chronic O O
experiments O O
on O O
dogs O O
with O O
gastric O O
fistulas O O
were O O
carried O O
out O O
to O O
study O O
the O O
influence O O
of O O
angiotensin B-Drug_n B-Group
9 I-Drug_n I-Group
and O O
angiotensin B-Drug_n B-Group
9 I-Drug_n I-Group
on O O
pentagastrin B-Drug B-Drug
- O O
and O O
histamine B-Drug B-Drug_n
- O O
induced O O
gastric O O
acid O O
secretion O O
. O O

Barbiturates B-Group O
and O O
glutethimide B-Drug B-Drug
should O O
not O O
be O O
administered O O
to O O
patients O O
receiving O O
coumarin B-Group B-Group
drugs I-Group I-Group
. O O

Excystment O O
in O O
vitro O O
was O O
only O O
significantly O O
affected O O
by O O
cercariae O O
exposed O O
to O O
cadmium O O
/ O O
zinc O O
mixtures O O
whilst O O
encysting O O
. O O

Therefore O O
we O O
investigated O O
the O O
effects O O
of O O
biocytin O O
inclusion O O
on O O
opioid B-Group O
responses O O
and O O
other O O
membrane O O
properties O O
during O O
whole O O
- O O
cell O O
tight O O
seal O O
recordings O O
of O O
these O O
neurons O O
. O O

In O O
addition O O
administration O O
to O O
a O O
patient O O
population O O
with O O
hepatic O O
insufficiency O O
resulted O O
in O O
a O O
9 O O
- O O
fold O O
increase O O
in O O
both O O
the O O
rate O O
and O O
extent O O
of O O
bioavailability O O
relative O O
to O O
controls O O
. O O

The O O
dissolution O O
rate O O
of O O
the O O
aerosol O O
particles O O
in O O
saline O O
was O O
low O O
and O O
variable O O
. O O

Cardiovascular O O
disease O O
is O O
a O O
common O O
comorbidity O O
and O O
a O O
major O O
cause O O
of O O
mortality O O
in O O
patients O O
with O O
chronic O O
renal O O
disease O O
. O O

The O O
implications O O
of O O
these O O
results O O
are O O
discussed O O
especially O O
with O O
respect O O
to O O
observations O O
which O O
indicate O O
that O O
homocysteine O O
may O O
be O O
a O O
precipitating O O
factor O O
in O O
the O O
development O O
of O O
thrombosis O O
. O O

Aortic O O
rings O O
with O O
intact O O
endothelium O O
from O O
the O O
high O O
- O O
dose O O
( O O
9 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
estradiol B-Drug B-Drug
group O O
were O O
supersensitive O O
to O O
noradrenaline B-Drug O
compared O O
to O O
the O O
vehicle O O
or O O
low O O
- O O
dose O O
( O O
9 O O
microg O O
/ O O
kg O O
/ O O
day O O
) O O
estradiol O B-Drug
groups O O
( O O
pD9 O O
values O O
= O O
9+ O O
/ O O
- O O
9 O O
9+ O O
/ O O
- O O
9 O O
and O O
9+ O O
/ O O
- O O
9 O O
respectively O O
) O O
. O O

Ibuprofen B-Drug O
plasma O O
concentration O O
was O O
also O O
increased O O
when O O
it O O
was O O
administered O O
with O O
piperine B-Drug_n B-Drug
. O O

Photic O O
evoked O O
potentials O O
were O O
recorded O O
from O O
the O O
visual O O
cortex O O
of O O
chronically O O
implanted O O
albino O O
rats O O
. O O

DESIGN O O
: O O
Open O O
- O O
label O O
three O O
- O O
phase O O
sequential O O
study O O
. O O

Differences O O
can O O
occur O O
in O O
therapeutic O O
effect O O
and O O
in O O
adverse O O
events O O
. O O

Administration O O
of O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoroacetone B-Drug_n B-Drug_n
( O O
9 O O
mg O O
kg O O
( O O
- O O
9 O O
) O O
body O O
weight O O
) O O
to O O
rats O O
in O O
vivo O O
resulted O O
in O O
( B-Drug_n O
- O O
) B-Drug_n O
- O O
erythro B-Drug_n B-Drug_n
- O O
fluorocitrate B-Drug_n B-Drug_n
synthesis O O
in O O
the O O
kidney O O
which O O
was O O
preceded O O
by O O
an O O
elevation O O
in O O
fluoride O O
levels O O
and O O
followed O O
by O O
citrate O O
accumulation O O
. O O

Flavoridin B-Drug_n B-Drug
alone O O
was O O
found O O
to O O
have O O
no O O
effect O O
on O O
CAS O O
but O O
can O O
completely O O
block O O
contortrostatin B-Drug_n B-Drug_n
- O O
induced O O
phosphorylation O O
of O O
this O O
protein O O
in O O
MDA O O
- O O
MB O O
- O O
9 O O
cells O O
. O O

The O O
role O O
of O O
p9 O O
( O O
Kip9 O O
) O O
in O O
dasatinib B-Drug B-Drug
- O O
enhanced O O
paclitaxel B-Drug B-Drug
cytotoxicity O O
in O O
human O O
ovarian O O
cancer O O
cells O O
. O O

The O O
mode O O
of O O
toxic O O
action O O
of O O
the O O
pesticide O O
gliftor B-Drug_n O
: O O
the O O
metabolism O O
of O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoroacetone B-Drug_n B-Drug_n
to O O
( B-Drug_n O
- O O
) B-Drug_n O
- O O
erythro B-Drug_n B-Drug_n
- O O
fluorocitrate B-Drug_n B-Drug_n
. O O

In O O
the O O
presence O O
of O O
phentolamine B-Drug B-Drug
( O O
9 O O
( O O
- O O
9 O O
) O O
M O O
) O O
the O O
second O O
contraction O O
was O O
inhibited O O
selectively O O
. O O

Differential O O
regulation O O
of O O
tyrosine O O
phosphorylation O O
in O O
tumor O O
cells O O
by O O
contortrostatin B-Drug_n B-Drug
a O O
homodimeric O O
disintegrin O O
and O O
monomeric O O
disintegrins O O
echistatin B-Drug_n B-Drug
and O O
flavoridin B-Drug_n B-Drug
. O O

We O O
demonstrate O O
that O O
the O O
conversion O O
of O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoro B-Drug_n B-Drug_n
- O O
9 B-Drug_n B-Drug_n
- O O
propanol B-Drug_n B-Drug_n
to O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoroacetone B-Drug_n B-Drug_n
by O O
an O O
NAD+ O O
- O O
dependent O O
oxidation O O
is O O
the O O
rate O O
- O O
limiting O O
step O O
in O O
the O O
synthesis O O
of O O
the O O
toxic O O
product O O
( O O
- O O
) O O
- O O
erythro B-Drug_n B-Drug_n
- O O
fluorocitrate B-Drug_n B-Drug_n
from O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoro B-Drug_n B-Drug_n
- O O
9 B-Drug_n B-Drug_n
- O O
propanol B-Drug_n B-Drug_n
. O O

According O O
to O O
Gibaldi O O
et O O
al O O
. O O

To O O
each O O
preparation O O
was O O
added O O
one O O
additional O O
drug O O
at O O
three O O
concentrations O O
ranging O O
from O O
therapeutic O O
to O O
toxic O O
. O O

Maximal O O
exercise O O
testing O O
a O O
maneuver O O
often O O
applied O O
to O O
cardiac O O
patients O O
does O O
not O O
significantly O O
alter O O
the O O
serum O O
digoxin B-Drug B-Drug
level O O
. O O

No O O
substantial O O
change O O
in O O
T O O
( O O
max O O
) O O
or O O
half O O
- O O
life O O
was O O
observed O O
. O O

At O O
9 O O
% O O
recovery O O
of O O
fade O O
hoof O O
twitch O O
was O O
9 O O
+ O O
/ O O
- O O
9 O O
% O O
for O O
atracurium B-Drug B-Drug
alone O O
and O O
9 O O
+ O O
/ O O
- O O
9 O O
% O O
for O O
atracurium B-Drug B-Drug
plus O O
gentamycin B-Drug B-Drug
. O O

SETTING O O
: O O
Rural O O
primary O O
care O O
centre O O
. O O

Medication O O
is O O
rarely O O
needed O O
. O O

Such O O
observations O O
prompted O O
to O O
investigate O O
the O O
ability O O
of O O
methylglyoxal B-Drug_n B-Drug
as O O
a O O
potent O O
drug O O
against O O
multidrug O O
resistant O O
Pseudomonas O O
aeruginosa O O
. O O

The O O
data O O
suggest O O
that O O
the O O
histidine O O
residues O O
may O O
be O O
crucial O O
to O O
the O O
receptor O O
- O O
binding O O
activity O O
of O O
toxin B-Drug_n B-Drug_n
A I-Drug_n I-Drug_n
. O O

It O O
is O O
therefore O O
necessary O O
to O O
be O O
well O O
acquainted O O
with O O
the O O
clinical O O
and O O
paraclinical O O
pattern O O
of O O
magnesium B-Drug B-Drug
deficit O O
and O O
to O O
discriminate O O
between O O
magnesium B-Drug B-Drug
deficiency O O
due O O
to O O
an O O
insufficient O O
magnesium B-Drug B-Drug
intake O O
which O O
only O O
requires O O
oral O O
physiological O O
supplementation O O
and O O
magnesium B-Drug B-Drug
depletion O O
related O O
to O O
a O O
dysregulation O O
of O O
the O O
control O O
mechanisms O O
of O O
magnesium B-Drug B-Drug
status O O
which O O
requires O O
more O O
or O O
less O O
specific O O
regulation O O
of O O
its O O
causal O O
dysregulation O O
. O O

and O O
the O O
remaining O O
9 O O
% O O
( O O
9 O O
% O O
CI O O
+ O O
/ O O
- O O
9 O O
) O O
by O O
monitoring O O
and O O
follow O O
- O O
up O O
of O O
patients O O
. O O

Misonidazole B-Drug_n O
protects O O
mouse O O
tumour O O
and O O
normal O O
tissues O O
from O O
the O O
toxicity O O
of O O
oral O O
CCNU B-Drug B-Drug
. O O

Calcium B-Drug B-Drug
doses O O
9 O O
mg O O
diminished O O
nonheme B-Drug B-Drug
iron I-Drug I-Drug
absorption O O
by O O
an O O
average O O
of O O
9 O O
% O O
. O O

Two O O
weeks O O
later O O
retinal O O
flatmounts O O
were O O
examined O O
for O O
GFP O O
expression O O
using O O
confocal O O
microscopy O O
. O O

There O O
was O O
no O O
change O O
after O O
a O O
single O O
dose O O
of O O
PGF9alpha B-Drug B-Drug
. O O

There O O
were O O
no O O
significant O O
differences O O
among O O
the O O
pD9 O O
values O O
for O O
noradrenaline B-Drug B-Drug
in O O
aortic O O
rings O O
without O O
endothelium O O
. O O

The O O
expression O O
of O O
EGFR O O
and O O
EGFR O O
ligands O O
was O O
determined O O
by O O
flow O O
cytometry O O
RT O O
- O O
PCR O O
and O O
real O O
- O O
time O O
quantitative O O
PCR O O
. O O

Hemoglobin O B-Drug
remained O O
unchanged O O
( O O
9 O O
9 O O
to O O
9 O O
9 O O
g O O
/ O O
l O O
) O O
while O O
darbepoetin B-Drug B-Drug
requirement O O
decreased O O
from O O
9 O O
( O O
9 O O
; O O
9 O O
) O O
to O O
9 O O
( O O
9 O O
; O O
9 O O
) O O
g O O
/ O O
week O O
p O O
= O O
9 O O
. O O

Depression O O
is O O
reaching O O
epidemic O O
proportions O O
in O O
the O O
western O O
world O O
. O O

These O O
results O O
suggest O O
that O O
oral O O
administration O O
of O O
dmPGE9 B-Drug_n B-Drug
induces O O
a O O
more O O
pronounced O O
secretory O O
diarrhea O O
in O O
cecectomized O O
than O O
in O O
control O O
rats O O
probably O O
due O O
to O O
the O O
lack O O
of O O
the O O
reservoir O O
function O O
of O O
the O O
cecum O O
in O O
the O O
operated O O
animals O O
. O O

Conclusions O O
and O O
the O O
types O O
of O O
studies O O
which O O
support O O
these O O
conclusions O O
are O O
given O O
for O O
each O O
major O O
section O O
. O O

ADL B-Drug B-Drug
- O O
9 B-Drug B-Drug_n
- O O
9 B-Drug O
is O O
a O O
novel O O
peripherally B-Group O
restricted I-Group O
opioid I-Group O
antagonist I-Group O
that O O
may O O
selectively O O
prevent O O
opioid B-Group O
- O O
induced O O
gastrointestinal O O
effects O O
without O O
reversing O O
analgesia O O
. O O

The O O
aim O O
of O O
this O O
paper O O
was O O
to O O
study O O
the O O
interaction O O
between O O
neurotensin B-Drug_n B-Drug
and O O
both O O
enkephalins B-Drug_n O
or O O
its O O
synthetic O B-Group
analogue O I-Group
D B-Drug_n I-Group
- O O
Ala9 B-Drug_n B-Drug_n
- O O
metenkephalinamide B-Drug_n O
or O O
tuftsin B-Drug_n O
on O O
the O O
antinonciceptive O O
effect O O
of O O
these O O
peptides O O
in O O
mice O O
after O O
intracisternal O O
injection O O
. O O

No O O
drug O O
interactions O O
with O O
simeticone B-Drug B-Drug
are O O
documented O O
in O O
the O O
current O O
summary O O
of O O
product O O
characteristics O O
. O O

All O O
9 O O
strains O O
of O O
enterococcus O O
three O O
strains O O
of O O
Clostridium O O
three O O
strains O O
of O O
Escherichia O O
coli O O
and O O
one O O
strain O O
of O O
Proteus O O
rettgeri O O
were O O
resistant O O
to O O
both O O
clindamycin B-Drug B-Drug
( O O
minimal O O
inhibitory O O
concentration O O
greater O O
than O O
9 O O
mug O O
/ O O
ml O O
) O O
and O O
gentamicin B-Drug B-Drug
( O O
minimal O O
inhibitory O O
concentration O O
greater O O
than O O
9 O O
mug O O
/ O O
ml O O
) O O
. O O

We O O
present O O
a O O
comprehensive O O
in O O
vitro O O
approach O O
to O O
assessing O O
metabolism O O
- O O
mediated O O
hepatotoxicity O O
using O O
male O O
Sprague O O
- O O
Dawley O O
rat O O
liver O O
slices O O
incubated O O
with O O
the O O
well O O
characterized O O
hepatotoxicant O O
precocene B-Drug_n B-Drug_n
I I-Drug_n I-Drug_n
and O O
inhibitors O O
of O O
cytochrome O O
P9 O O
( O O
CYP O O
) O O
enzymes O O
. O O

At O O
9 O O
mg O O
/ O O
kg O O
the O O
diarrhea O O
- O O
inducing O O
effects O O
of O O
dmPGE9 B-Drug_n B-Drug_n
were O O
more O O
pronounced O O
in O O
cecectomized O O
than O O
in O O
control O O
rats O O
. O O

aureus O O
to O O
survive O O
in O O
pentazocine B-Drug B-Drug
and O O
tripelennamine B-Drug B-Drug
may O O
explain O O
in O O
part O O
a O O
shift O O
from O O
S O O
. O O

Moreover O O
combination O O
of O O
celecoxib B-Drug B-Drug
with O O
other O O
drugs O O
should O O
be O O
tailored O O
to O O
the O O
tumor O O
type O O
drug O O
and O O
administration O O
schedule O O
. O O

The O O
FDA O O
has O O
approved O O
ticagrelor B-Drug O
( O O
Brilinta B-Brand O
- O O
AstraZeneca O O
) O O
an O O
oral O O
antiplatelet B-Group O
drug I-Group O
for O O
use O O
with O O
low O O
- O O
dose O O
aspirin B-Brand O
to O O
reduce O O
the O O
rate O O
of O O
thrombotic O O
cardiovascular O O
events O O
in O O
patients O O
with O O
acute O O
coronary O O
syndrome O O
( O O
ACS O O
) O O
. O O

Results O O
showed O O
that O O
depending O O
on O O
the O O
task O O
considered O O
the O O
same O O
pharmacological O O
treatment O O
produced O O
either O O
a O O
facilitation O O
or O O
an O O
impairment O O
of O O
acquisition O O
. O O

The O O
different O O
responses O O
in O O
locomotor O O
activity O O
induced O O
by O O
cocaine B-Drug B-Drug
suggest O O
that O O
genetic O O
factors O O
may O O
play O O
a O O
role O O
in O O
determining O O
the O O
magnitude O O
of O O
response O O
to O O
this O O
drug O O
. O O

To O O
date O O
there O O
is O O
no O O
conclusive O O
evidence O O
of O O
a O O
clinically O O
- O O
relevant O O
interaction O O
between O O
any O O
of O O
the O O
proton B-Group B-Group
pump I-Group I-Group
inhibitors I-Group I-Group
and O O
clopidogrel B-Drug B-Drug
. O O

Activation O O
of O O
an O O
effector O O
immediate O O
- O O
early O O
gene O O
arc O O
by O O
methamphetamine B-Drug B-Drug
. O O

This O O
study O O
aimed O O
to O O
evaluate O O
the O O
in O O
vitro O O
activity O O
of O O
minocycline B-Drug B-Drug
combined O O
with O O
fosfomycin B-Drug B-Drug
against O O
isolates O O
of O O
methicillin B-Drug B-Drug
- O O
resistant O O
Staphylococcus O O
aureus O O
( O O
MRSA O O
) O O
. O O

By O O
inhibiting O O
the O O
metabolism O O
of O O
drugs O O
piperine B-Drug_n O
improves O O
the O O
bioavailability O O
of O O
drugs O O
. O O

The O O
world O O
medical O O
literature O O
contains O O
9 O O
reports O O
of O O
deaths O O
associated O O
with O O
amphetamines B-Drug O
in O O
a O O
9 O O
- O O
year O O
period O O
. O O

Ultimately O O
however O O
up O O
to O O
9 O O
% O O
of O O
type O O
9 O O
diabetics O O
die O O
from O O
macrovascular O O
cardiovascular O O
disease O O
. O O

Further O O
no O O
effects O O
on O O
either O O
warfarin B-Drug B-Drug
levels O O
or O O
prothrombin O O
times O O
were O O
observed O O
in O O
a O O
study O O
involving O O
concomitant O O
administration O O
of O O
warfarin B-Drug B-Drug
and O O
fluvastatin B-Drug B-Drug
. O O

Cysteine B-Drug B-Drug
conjugation O O
at O O
9 O O
9 O O
and O O
9 O O
% O O
( O O
m O O
/ O O
m O O
) O O
resulted O O
in O O
R O O
- O O
values O O
of O O
9 O O
9 O O
and O O
9 O O
respectively O O
. O O

Recombinant O O
shuttle O O
vectors O O
containing O O
a O O
vanH O O
promoter O O
- O O
vanA O O
antisense O O
gene O O
cassette O O
fully O O
restored O O
vancomycin B-Drug B-Drug
susceptibility O O
through O O
a O O
combined O O
transcriptional O O
activator O O
binding O O
domain O O
decoy O O
and O O
inducible O O
vanA O O
antisense O O
RNA O O
effect O O
. O O

The O O
simplest O O
inference O O
is O O
that O O
the O O
toxicity O O
and O O
effectiveness O O
of O O
polyenes O O
are O O
determined O O
by O O
their O O
relative O O
avidities O O
for O O
the O O
predominant O O
sterol O O
in O O
cell O O
membranes O O
. O O

These O O
observations O O
suggest O O
that O O
exogenous O O
co O O
- O O
factors O O
could O O
be O O
involved O O
in O O
the O O
occurrence O O
of O O
ARE O O
. O O

Acid O O
secretion O O
in O O
isolated O O
rabbit O O
gastric O O
glands O O
was O O
monitored O O
by O O
the O O
accumulation O O
of O O
[ O O
( O O
9 O O
) O O
C O O
] O O
aminopyrine B-Drug B-Drug
. O O

[ O O
Interaction O O
between O O
clopidogrel B-Drug B-Drug
and O O
proton B-Group B-Group
pump I-Group I-Group
inhibitors I-Group I-Group
] O O
. O O

Interferon O O
induction O O
: O O
tool O O
for O O
establishing O O
interactions O O
among O O
homopolyribonucleotides O O
. O O

The O O
synergistic O O
antinociception O O
activity O O
of O O
ibuprofen B-Drug B-Drug
when O O
administered O O
with O O
piperine B-Drug_n B-Drug
can O O
be O O
attributed O O
to O O
increased O O
plasma O O
concentration O O
of O O
ibuprofen B-Drug B-Drug
. O O

Prevention O O
of O O
emergence O O
agitation O O
in O O
seven O O
children O O
receiving O O
low O O
- O O
dose O O
ketamine B-Drug B-Drug
and O O
propofol B-Drug B-Drug
total O O
intravenous O O
anesthesia O O
. O O

Olanzapine B-Drug B-Drug
is O O
associated O O
with O O
significantly O O
fewer O O
extrapyramidal O O
symptoms B-Group O
than O O
haloperidol B-Drug B-Drug
and O O
risperidone B-Drug B-Drug
. O O

However O O
administration O O
of O O
9 B-Drug B-Drug_n
- O O
methylpyrazole B-Drug B-Drug
( O O
9 O O
mg O O
kg O O
( O O
- O O
9 O O
) O O
body O O
weight O O
) O O
to O O
rats O O
9 O O
hours O O
prior O O
to O O
9 B-Drug_n O
9 I-Drug_n O
- O O
difluoroacetone B-Drug_n B-Drug_n
( O O
9 O O
mg O O
kg O O
( O O
- O O
9 O O
) O O
body O O
weight O O
) O O
was O O
ineffective O O
in O O
preventing O O
( B-Drug_n O
- O O
) B-Drug_n O
- O O
erythro B-Drug_n B-Drug_n
- O O
fluorocitrate B-Drug_n B-Group
synthesis O I-Group
and O O
did O O
not O O
diminish O O
fluoride O O
or O O
citrate O O
accumulation O O
in O O
vivo O O
. O O

The O O
effects O O
of O O
supplementary O O
oral O O
cobalt B-Drug B-Drug
and O O
iron B-Drug B-Drug
as O O
well O O
as O O
the O O
interaction O O
between O O
both O O
at O O
the O O
absorption O O
site O O
fecal O O
and O O
urinary O O
excretion O O
as O O
well O O
as O O
the O O
retention O O
of O O
these O O
trace O O
elements O O
were O O
determined O O
by O O
using O O
four O O
diets O O
containing O O
either O O
9 O O
or O O
9 O O
micrograms O O
/ O O
kg O O
of O O
Co B-Drug O
and O O
9 O O
or O O
9 O O
mg O O
/ O O
kg O O
of O O
Fe B-Drug B-Drug
over O O
a O O
period O O
of O O
9 O O
days O O
in O O
a O O
total O O
of O O
9 O O
rats O O
. O O

These O O
differences O O
were O O
reflected O O
in O O
the O O
roughly O O
twofold O O
greater O O
antitumour O O
activity O O
for O O
the O O
oral O O
route O O
. O O

RESULTS O O
: O O
Everolimus B-Drug B-Drug
steady O O
state O O
was O O
reached O O
on O O
or O O
before O O
day O O
9 O O
with O O
a O O
median O O
9 O O
- O O
fold O O
accumulation O O
of O O
drug O O
exposure O O
compared O O
with O O
that O O
after O O
the O O
first O O
postoperative O O
dose O O
. O O

the O O
third O O
group O O
( O O
SH O O
/ O O
EA O O
) O O
was O O
treated O O
with O O
a O O
hydroalcoholic O O
solution O O
of O O
ethanol B-Drug B-Drug
; O O

In O O
dogs O O
cimetidine B-Drug O
unchanged O O
the O O
secretion O O
of O O
cardiotrast B-Drug O
a O O
test O O
agent O O
for O O
anionic O O
transport O O
. O O

Twelve O O
strains O O
of O O
Staphylococcus O O
aureus O O
( O O
a O O
frequent O O
cause O O
of O O
infection O O
in O O
heroin B-Drug_n B-Drug
but O O
not O O
in O O
pentazocine B-Drug B-Drug
and O O
tripelennamine B-Drug B-Drug
addicts O O
) O O
were O O
completely O O
inhibited O O
by O O
the O O
drug O O
combination O O
. O O

Differential O O
actions O O
of O O
intrathecal O O
naloxone B-Drug B-Drug
on O O
blocking O O
the O O
tail O O
- O O
flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta B-Drug_n B-Drug_n
- O O
endorphin B-Drug_n B-Drug_n
and O O
morphine B-Drug B-Drug
in O O
rats O O
. O O

The O O
IC O O
( O O
9 O O
) O O
was O O
about O O
9 O O
microgram O O
/ O O
ml O O
. O O

But O O
it O O
is O O
now O O
difficult O O
to O O
situate O O
the O O
exact O O
place O O
of O O
the O O
pharmacological O O
indications O O
of O O
magnesium B-Drug B-Drug
. O O

Inhibition O O
of O O
Src O O
family O O
and O O
Abl O O
kinases O O
with O O
either O O
siRNAs O O
or O O
dasatinib B-Drug B-Drug
enhances O O
paclitaxel B-Drug B-Drug
sensitivity O O
of O O
ovarian O O
cancer O O
cells O O
through O O
p9 O O
( O O
Kip9 O O
) O O
- O O
mediated O O
suppression O O
of O O
Bcl O O
- O O
9 O O
and O O
Cdk9 O O
expression O O
. O O

Influence O O
of O O
piperine B-Drug_n B-Drug
on O O
ibuprofen B-Drug B-Drug
induced O O
antinociception O O
and O O
its O O
pharmacokinetics O O
. O O

Determinants O O
of O O
cellular O O
sensitivity O O
to O O
topoisomerase B-Group O
- O O
targeting B-Group O
antitumor I-Group O
drugs I-Group O
. O O

Medicaid O O
claims O O
data O O
( O O
9 O O
- O O
9 O O
) O O
were O O
used O O
to O O
perform O O
an O O
observational O O
case O O
- O O
control O O
study O O
nested O O
within O O
person O O
- O O
time O O
exposed O O
to O O
warfarin B-Drug B-Drug
in O O
those O O
9 O O
years O O
. O O

diseases O O
of O O
the O O
liver O O
gallbladder O O
and O O
bowel O O
; O O

NNRTI B-Group B-Drug
- O O
based O O
regimens O O
may O O
have O O
several O O
advantages O O
over O O
PI B-Group B-Drug_n
- O O
based O O
therapy O O
for O O
initial O O
or O O
prolonged O O
therapy O O
including O O
more O O
convenient O O
administration O O
regimens O O
lower O O
tablet O O
volume O O
fewer O O
drug O O
interactions O O
and O O
central O O
nervous O O
system O O
penetration O O
. O O

The O O
proposed O O
mechanisms O O
of O O
analgesic O O
action O O
of O O
antihistaminics B-Group B-Drug
are O O
reviewed O O
and O O
discussed O O
. O O

The O O
effects O O
of O O
coadministered O B-Group
drugs O I-Group
and O O
ethanol B-Drug B-Drug
on O O
the O O
binding O O
of O O
therapeutic O O
drugs O O
to O O
human O O
serum O O
in O O
vitro O O
was O O
investigated O O
. O O

Furthermore O O
down O O
- O O
regulation O O
of O O
ALOX9 O O
by O O
RNA O O
interference O O
could O O
also O O
induce O O
apoptosis O O
in O O
H9 O O
. O O

Withdrawal O O
of O O
rifampin B-Drug B-Drug
decreased O O
the O O
warfarin B-Drug B-Drug
requirement O O
by O O
9 O O
% O O
. O O

Cholestyramine B-Drug B-Drug
an O O
anionic O O
- O O
binding O O
resin O O
has O O
a O O
considerable O O
effect O O
in O O
lowering O O
the O O
rate O O
and O O
extent O O
of O O
fluvastatin B-Drug B-Drug
bioavailability O O
. O O

Together O O
with O O
previous O O
findings O O
these O O
results O O
suggest O O
that O O
the O O
hippocampus O O
is O O
involved O O
in O O
both O O
the O O
so O O
- O O
called O O
`` O O
hippocampal O O
- O O
dependent O O
'' O O

Inhibitory O O
effects O O
of O O
ruthenium B-Drug_n O
red I-Drug_n O
on O O
inositol O O
9 O O
9 O O
9 O O
- O O
trisphosphate O O
- O O
induced O O
responses O O
in O O
rat O O
megakaryocytes O O
. O O

Absorption O O
of O O
fluvastatin B-Drug B-Drug
is O O
virtually O O
complete O O
across O O
all O O
species O O
including O O
man O O
and O O
is O O
not O O
affected O O
by O O
the O O
presence O O
of O O
food O O
. O O

We O O
conclude O O
that O O
the O O
prophylactic O O
and O O
antidotal O O
properties O O
of O O
9 B-Drug B-Drug_n
- O O
methylpyrazole B-Drug B-Drug
seen O O
in O O
animals O O
treated O O
with O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoro B-Drug_n B-Drug_n
- O O
9 B-Drug_n B-Drug_n
- O O
propanol B-Drug_n B-Drug_n
derive O O
from O O
its O O
capacity O O
to O O
inhibit O O
the O O
NAD+ O O
- O O
dependent O O
oxidation O O
responsible O O
for O O
converting O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoro B-Drug_n B-Drug_n
- O O
9 B-Drug_n B-Drug_n
- O O
propanol B-Drug_n B-Drug_n
to O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
- O O
difluoroacetone B-Drug_n B-Drug_n
in O O
the O O
committed O O
step O O
of O O
the O O
toxic O O
pathway O O
. O O

Warfarin B-Drug B-Drug
users O O
had O O
an O O
increased O O
odds O O
ratio O O
of O O
gastrointestinal O O
bleeding O O
upon O O
initiation O O
of O O
citalopram B-Drug B-Drug
( O O
OR O O
= O O
9 O O
[ O O
9 O O
% O O
CI O O
9 O O
- O O
9 O O
] O O
) O O
fluoxetine B-Drug B-Drug
( O O
OR O O
= O O
9 O O
[ O O
9 O O
% O O
CI O O
9 O O
- O O
9 O O
] O O
) O O
paroxetine B-Drug B-Drug
( O O
OR O O
= O O
9 O O
[ O O
9 O O
% O O
CI O O
9 O O
- O O
9 O O
] O O
) O O
amitriptyline B-Drug B-Drug
( O O
OR O O
= O O
9 O O
[ O O
9 O O
% O O
CI O O
9 O O
- O O
9 O O
] O O
) O O
. O O

Electrocardiograms O O
were O O
done O O
at O O
baseline O O
and O O
on O O
the O O
last O O
day O O
of O O
the O O
washout O O
period O O
and O O
phase O O
9 O O
. O O

We O O
found O O
antagonism O O
between O O
celecoxib B-Drug B-Drug
and O O
the O O
four O O
drugs O O
in O O
the O O
breast O O
cancer O O
cells O O
MCF9 O O
following O O
all O O
incubation O O
schedules O O
and O O
between O O
celecoxib B-Drug B-Drug
and O O
doxorubicin B-Drug B-Drug
in O O
all O O
cell O O
lines O O
except O O
for O O
two O O
combinations O O
in O O
HCT9 O O
cells O O
. O O

Pharmacokinetics O O
of O O
calcium B-Group B-Drug
- O O
entry B-Group B-Group
blockers I-Group I-Group
. O O

For O O
digoxin B-Drug B-Drug
AUC O O
( O O
9 O O
- O O
infinity O O
) O O
AUC O O
( O O
9 O O
- O O
9 O O
) O O
and O O
Cmax O O
the O O
geometric O O
mean O O
ratios O O
( O O
9 O O
% O O
confidence O O
interval O O
) O O
for O O
( O O
rofecoxib B-Drug B-Drug
+ O O
digoxin B-Drug B-Drug
/ O O
placebo O O
+ O O
digoxin B-Drug B-Drug
) O O
were O O
9 O O
( O O
9 O O
9 O O
) O O
9 O O
( O O
9 O O
9 O O
) O O
and O O
9 O O
( O O
9 O O
9 O O
) O O
respectively O O
. O O

however O O
a O O
comparison O O
of O O
fluvastatin B-Drug B-Drug
administration O O
with O O
the O O
evening O O
meal O O
or O O
at O O
bedtime O O
has O O
revealed O O
no O O
significant O O
differences O O
in O O
the O O
extent O O
of O O
bioavailability O O
( O O
area O O
under O O
the O O
curve O O
) O O
of O O
these O O
two O O
regimens O O
. O O

Calcium B-Drug B-Drug
was O O
administered O O
as O O
calcium B-Drug O
chloride I-Drug O
in O O
all O O
studies O O
and O O
minerals B-Group B-Drug
were O O
ingested O O
on O O
an O O
empty O O
stomach O O
. O O

At O O
9 O O
degrees O O
C O O
the O O
non O O
- O O
myelinated O O
axons O O
contained O O
9 O O
plus O O
or O O
minus O O
9 O O
S.E.M O O
. O O

Specifically O O
they O O
have O O
focused O O
on O O
aspects O O
of O O
learning O O
and O O
memory O O
that O O
are O O
impaired O O
( O O
vs. O O
spared O O
) O O
by O O
lesions O O
of O O
the O O
hippocampal O O
formation O O
. O O

After O O
9 O O
h O O
atracurium B-Drug B-Drug
was O O
discontinued O O
and O O
hoof O O
twitch O O
allowed O O
to O O
recover O O
to O O
9 O O
% O O
. O O

In O O
these O O
six O O
cases O O
it O O
was O O
demonstrated O O
that O O
the O O
neuroleptics B-Group O
dosage O O
was O O
inappropriate O O
being O O
either O O
too O O
high O O
or O O
too O O
low O O
as O O
judged O O
from O O
the O O
plasma O O
concentrations O O
. O O

The O O
majority O O
of O O
adverse O O
events O O
with O O
NNRTIs B-Group O
occur O O
within O O
the O O
first O O
month O O
and O O
are O O
predictable O O
and O O
manageable O O
without O O
therapy O O
interruption O O
. O O

It O O
was O O
observed O O
that O O
MPTP B-Drug_n B-Drug
induced O O
long O O
lasting O O
depletions O O
of O O
striatal O O
dopamine O O
concentrations O O
and O O
this O O
neurotoxic O O
effect O O
could O O
be O O
prevented O O
by O O
pargyline B-Drug B-Drug
pretreatment O O
. O O

The O O
incidence O O
of O O
ARE O O
suddenly O O
exceeded O O
9 O O
% O O
of O O
the O O
patients O O
treated O O
by O O
melarsoprol B-Drug B-Drug
during O O
August O O
9 O O
and O O
September O O
9 O O
. O O

In O O
the O O
current O O
study O O
the O O
nonpredisposed O O
strain O O
C9BL O O
/ O O
9N O O
was O O
also O O
shown O O
to O O
be O O
highly O O
susceptible O O
to O O
diethylnitrosamine O O
during O O
the O O
neonatal O O
period O O
. O O

A O O
method O O
to O O
maximize O O
the O O
therapeutic O O
benefit O O
of O O
gentamicin B-Drug B-Drug
while O O
minimizing O O
the O O
risk O O
of O O
nephrotoxicity O O
and O O
the O O
appearance O O
of O O
a O O
hot O O
kidney O O
on O O
scintigraphy O O
is O O
desirable O O
. O O

Effect O O
of O O
rofecoxib B-Drug B-Drug
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-Drug B-Drug
in O O
healthy O O
volunteers O O
. O O

Except O O
for O O
clindamycin B-Drug B-Drug
- O O
sensitive O O
isolates O O
synergy O O
was O O
usually O O
observed O O
only O O
at O O
concentrations O O
of O O
one O O
or O O
both O O
drugs O O
which O O
are O O
not O O
readily O O
obtainable O O
in O O
vivo O O
. O O

The O O
objective O O
was O O
to O O
analyze O O
the O O
effects O O
of O O
neonatal O O
quinpirole B-Drug_n O
treatment O O
on O O
effects O O
of O O
amphetamine B-Drug B-Drug
in O O
adolescent O O
rats O O
using O O
locomotor O O
sensitization O O
and O O
conditioned O O
place O O
preference O O
procedures O O
. O O

We O O
could O O
observe O O
that O O
ginsenosides B-Drug_n B-Drug
inhibited O O
high O O
threshold O O
voltage O O
- O O
dependent O O
Ca O O
( O O
9+ O O
) O O
currents O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

In O O
previous O O
reports O O
we O O
have O O
shown O O
that O O
ginsenosides B-Drug_n B-Drug
inhibit O O
high O O
threshold O O
voltage O O
- O O
dependent O O
Ca O O
( O O
9+ O O
) O O
channels O O
in O O
neuronal O O
cells O O
. O O

Serum O O
digoxin B-Drug B-Drug
levels O O
using O O
an O O
9I O O
- O O
labelled O O
antigen O O
: O O
Validation O O
of O O
method O O
and O O
observations O O
on O O
cardiac O O
patients O O
. O O

This O O
might O O
be O O
explained O O
by O O
a O O
blockade O O
by O O
probenecid B-Drug O
of O O
the O O
elimination O O
of O O
cloxacillin B-Drug B-Drug
by O O
the O O
liver O O
. O O

Stimulation O O
of O O
the O O
glands O O
with O O
carbachol B-Drug B-Drug
synergistically O O
augmented O O
the O O
response O O
to O O
dibutyryl O O
cAMP O O
. O O

Twenty O O
- O O
four O O
healthy O O
male O O
subjects O O
were O O
randomized O O
to O O
one O O
of O O
two O O
cohorts O O
. O O

The O O
fluoroquinolones B-Group B-Drug
are O O
a O O
rapidly O O
growing O O
class O O
of O O
antibiotics B-Group B-Drug
with O O
a O O
broad O O
spectrum O O
of O O
activity O O
against O O
gram O O
- O O
negative O O
and O O
some O O
gram O O
- O O
positive O O
aerobic O O
bacteria O O
. O O

Male O O
rats O O
demonstrated O O
sensitization O O
to O O
amphetamine B-Drug B-Drug
although O O
this O O
was O O
muted O O
compared O O
with O O
female O O
rats O O
and O O
were O O
unaffected O O
by O O
neonatal O O
quinpirole B-Drug_n O
. O O

Growth O O
inhibition O O
in O O
vitro O O
was O O
additive O O
with O O
the O O
two O O
drugs O O
. O O

Again O O
sertraline B-Drug B-Drug
neutralized O O
the O O
increase O O
in O O
glycemia O O
after O O
glucose B-Drug O
overload O O
both O O
in O O
diabetic O O
and O O
non O O
- O O
diabetic O O
rats O O
. O O

CONCLUSIONS O O
: O O
Everolimus B-Drug B-Drug
exhibited O O
dose O O
- O O
proportional O O
stable O O
exposure O O
during O O
the O O
first O O
post O O
- O O
transplant O O
year O O
. O O

longum O O
is O O
a O O
known O O
inhibitor O O
of O O
various O O
enzymes O O
( O O
CYP O O
isozymes O O
) O O
responsible O O
for O O
biotransformation O O
of O O
drugs O O
. O O

acanthus O O
. O O

Blood O O
samples O O
also O O
were O O
taken O O
before O O
morning O O
doses O O
on O O
the O O
9rd O O
9th O O
and O O
9th O O
days O O
of O O
phases O O
9 O O
and O O
9 O O
. O O

Antiretroviral B-Group O
plasma O O
and O O
urine O O
sampling O O
were O O
conducted O O
on O O
Days O O
9 O O
9 O O
and O O
9 O O
for O O
zidovudine B-Drug B-Drug
and O O
on O O
Days O O
9 O O
and O O
9 O O
for O O
dideoxyinosine B-Drug B-Drug
. O O

No O O
significant O O
difference O O
was O O
found O O
between O O
the O O
mean O O
values O O
of O O
the O O
volume O O
of O O
distribution O O
of O O
cloxacillin B-Drug B-Drug
with O O
and O O
without O O
probenecid B-Drug B-Drug
( O O
9 O O
and O O
9 O O
liters O O
respectively O O
) O O
. O O

The O O
hatching O O
of O O
miracidia O O
from O O
eggs O O
was O O
inhibited O O
by O O
concentrations O O
of O O
9 O O
- O O
99 O O
microg O O
/ O O
l O O
of O O
single O O
metals O O
. O O

In O O
vivo O O
CYP9A O O
activity O O
is O O
significantly O O
lower O O
in O O
cyclosporine B-Drug B-Drug
- O O
treated O O
as O O
compared O O
with O O
tacrolimus B-Drug B-Drug
- O O
treated O O
renal O O
allograft O O
recipients O O
. O O

nitrosourea B-Group B-Drug
AUC O O
with O O
the O O
extent O O
of O O
the O O
reduction O O
depending O O
on O O
the O O
minimum O O
effective O O
concentration O O
( O O
MEC O O
) O O
chosen O O
. O O

Two O O
retrospective O O
studies O O
were O O
conducted O O
in O O
9 O O
( O O
9 O O
cases O O
) O O
and O O
in O O
9 O O
( O O
9 O O
cases O O
) O O
. O O

fecal O O
excretion O O
too O O
was O O
increased O O
by O O
supplementary O O
iron B-Drug B-Drug
; O O

Glucose B-Drug B-Drug
alone O O
and O O
in O O
the O O
presence O O
of O O
theophylline B-Drug B-Drug
caused O O
subnormal O O
insulin O O
release O O
and O O
less O O
suppression O O
of O O
glucagon O O
release O O
in O O
the O O
diabectics O O
than O O
in O O
the O O
normals O O
. O O

SETTING O O
: O O
Clinical O O
research O O
center O O
. O O

uterine O O
fibroids O O
; O O

Antidepressant B-Group B-Drug_n
- O O
warfarin B-Drug B-Drug
interaction O O
and O O
associated O O
gastrointestinal O O
bleeding O O
risk O O
in O O
a O O
case O O
- O O
control O O
study O O
. O O

It O O
was O O
concluded O O
that O O
although O O
gentamycin B-Drug B-Drug
did O O
augment O O
the O O
neuromuscular O O
blockade O O
of O O
atracurium B-Drug B-Drug
the O O
effect O O
was O O
minimal O O
. O O

Postoperatively O O
9 O O
patients O O
were O O
randomly O O
assigned O O
in O O
a O O
double O O
- O O
blind O O
fashion O O
to O O
receive O O
ADL B-Drug B-Drug
9 I-Drug I-Drug
- O O
9 B-Drug O
( O O
9 O O
mg O O
) O O
or O O
placebo O O
and O O
intravenous O O
morphine B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
or O O
to O O
receive O O
oral O O
and O O
intravenous O O
placebo O O
. O O

and O O
/ O O
or O O
antibiotic B-Group B-Group
drug I-Group I-Group
doxycycline B-Drug B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
p O O
. O O
o O O
. O O
) O O
as O O
well O O
as O O
that O O
of O O
neurotoxin O B-Drug
9 B-Drug_n I-Drug
- O O
methyl B-Drug_n B-Drug_n
- O O
9 B-Drug_n B-Drug_n
- O O
phenyl B-Drug_n B-Drug_n
- O O
9 B-Drug_n B-Drug_n
9 I-Drug_n I-Drug_n
9 I-Drug_n I-Drug_n
9 I-Drug_n I-Drug_n
- O O
tetrahydropyridine B-Drug_n B-Drug_n
( O O
MPTP B-Drug_n B-Drug_n
) O O
( O O
9 O O
x O O
9 O O
mg O O
/ O O
kg O O
i. O O
p O O
. O O
) O O

The O O
findings O O
suggest O O
that O O
the O O
agent O O
has O O
slight O O
effects O O
on O O
the O O
tested O O
activities O O
. O O

The O O
effects O O
of O O
ruthenium B-Drug_n O
red I-Drug_n O
( O O
RR B-Drug_n B-Drug_n
) O O
on O O
inositol B-Drug_n O
9 I-Drug_n O
9 I-Drug_n O
9 I-Drug_n O
- O O
trisphosphate B-Drug_n B-Drug_n
( O O
InsP9 B-Drug_n B-Drug_n
) O O
- O O
induced O O
responses O O
were O O
studied O O
in O O
rat O O
bone O O
marrow O O
megakaryocytes O O
with O O
the O O
patch O O
- O O
clamp O O
whole O O
- O O
cell O O
recording O O
technique O O
in O O
combination O O
with O O
fura O O
- O O
9 O O
microfluorometry O O
. O O

The O O
influence O O
of O O
the O O
other O O
proton B-Group B-Group
pump I-Group I-Group
inhibitors I-Group I-Group
when O O
used O O
simultaneously O O
with O O
clopidogrel B-Drug B-Drug
has O O
not O O
yet O O
been O O
investigated O O
in O O
adequately O O
randomized O O
studies O O
. O O

[ O O
The O O
GABA O O
- O O
ergic O O
system O O
and O O
brain O O
edema O O
] O O
It O O
has O O
been O O
shown O O
in O O
rats O O
with O O
experimental O O
toxic O O
and O O
traumatic O O
edemas O O
that O O
picrotoxin B-Drug_n B-Drug
( O O
9 O O
mg O O
/ O O
kg O O
) O O
removes O O
the O O
antiedematous O O
action O O
of O O
diazepam B-Drug B-Group
phenazepam B-Drug_n I-Group
phenibut B-Drug_n I-Group
and O O
amizyl B-Drug_n O
and O O
reduces O O
the O O
action O O
of O O
phentolamine B-Drug B-Drug
. O O

and O O
a O O
variety O O
of O O
putative O O
protective O O
compounds O O
including O O
antioxidants O O
and O O
mitochondrial O O
protective O O
agents O O
. O O

The O O
plasma O O
and O O
tumour O O
total O O
nitrosourea B-Group B-Drug
peak O O
concentrations O O
were O O
reduced O O
by O O
9 O O
and O O
9 O O
fold O O
respectively O O
. O O

Green B-Drug O
tea I-Drug O
polyphenols I-Drug O
as O O
potent O O
enhancers B-Drug O
of O O
glucocorticoid O O
- O O
induced O O
mouse O O
mammary O O
tumor O O
virus O O
gene O O
expression O O
. O O

Imexon B-Drug O
and O O
dacarbazine B-Drug B-Drug
show O O
additive O O
effects O O
in O O
vitro O O
but O O
not O O
in O O
vivo O O
in O O
human O O
A9 O O
melanoma O O
cells O O
. O O

The O O
blockade O O
of O O
the O O
spinal O O
endorphinergic O O
system O O
by O O
intrathecal O O
naloxone B-Drug B-Drug
on O O
the O O
production O O
of O O
tail O O
- O O
flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta B-Drug_n B-Drug_n
- O O
endorphin B-Drug_n B-Drug_n
and O O
morphine B-Drug B-Drug
was O O
then O O
studied O O
. O O

Cholecystokinin O B-Drug
octapeptide O O
is O O
a O O
necessary O O
factor O O
for O O
realization O O
of O O
this O O
action O O
of O O
neuroleptics B-Group B-Drug
. O O

This O O
is O O
demonstrated O O
for O O
cigarette O O
smokers O O
and O O
industrial O O
workers O O
involved O O
in O O
chemical O O
waste O O
incineration O O
. O O

Distinct O O
synergistic O O
action O O
of O O
piperacillin B-Drug B-Drug
and O O
methylglyoxal B-Drug_n B-Drug
against O O
Pseudomonas O O
aeruginosa O O
. O O

Potential O O
differences O O
in O O
cyclosporine B-Drug B-Drug
dosing O O
and O O
pharmacokinetics O O
at O O
different O O
levels O O
of O O
everolimus B-Drug B-Drug
exposure O O
were O O
assessed O O
in O O
the O O
context O O
of O O
ANOVA O O
. O O

With O O
each O O
successive O O
generation O O
more O O
people O O
are O O
becoming O O
more O O
severely O O
depressed O O
at O O
a O O
younger O O
age O O
. O O

Sildenafil B-Drug B-Drug
is O O
contraindicated O O
in O O
patients O O
using O O
long B-Group O
- O O
acting B-Group O
nitrates I-Group O
or O O
who O O
may O O
need O O
to O O
use O O
short B-Group O
- O O
acting B-Group O
nitrates I-Group O
because O O
the O O
combination O O
may O O
cause O O
a O O
sharp O O
fall O O
of O O
the O O
blood O O
pressure O O
. O O

The O O
serum O O
estrogen O O
concentrations O O
of O O
estradiol B-Drug B-Drug
+ O I-Drug
endotoxin B-Drug_n B-Drug_n
- O O
treated O O
rats O O
decreased O O
by O O
9 O O
% O O
while O O
those O O
of O O
the O O
endotoxin B-Drug_n B-Drug_n
- O O
treated O O
rats O O
increased O O
( O O
9 O O
- O O
to O O
9 O O
- O O
fold O O
) O O
. O O

In O O
other O O
cells O O
it O O
enhances O O
drug O O
- O O
induced O O
G9 O O
/ O O
M O O
arrest O O
allowing O O
time O O
to O O
repair O O
drug O O
- O O
induced O O
DNA O O
damage O O
before O O
entry O O
into O O
mitosis O O
and O O
decreasing O O
cell O O
death O O
resulting O O
in O O
antagonism O O
. O O

however O O
no O O
significant O O
difference O O
in O O
the O O
maximum O O
concentration O O
in O O
plasma O O
or O O
the O O
area O O
under O O
the O O
concentration O O
- O O
time O O
curve O O
from O O
time O O
zero O O
to O O
9 O O
h O O
was O O
observed O O
. O O

Concomitant O O
use O O
of O O
omeprazole B-Drug B-Drug
and O O
clopidogrel B-Drug B-Drug
was O O
found O O
to O O
decrease O O
the O O
exposure O O
( O O
AUC O O
) O O
to O O
clopidogrel O B-Drug
's O O
active O O
metabolite O O
by O O
9 O O
% O O
and O O
to O O
sharply O O
increase O O
platelet O O
reactivity O O
as O O
a O O
result O O
of O O
inhibition O O
by O O
omeprazole B-Drug O
of O O
CYP9C9 O B-Drug
a O O
cytochrome O O
P9 O O
( O O
CYP O O
) O O
enzyme O O
. O O

In O O
order O O
to O O
approximate O O
the O O
steady O O
state O O
level O O
serum O O
digoxin B-Drug B-Drug
levels O O
should O O
be O O
drawn O O
either O O
before O O
or O O
at O O
least O O
six O O
hours O O
following O O
the O O
administration O O
of O O
an O O
oral O O
tablet O O
. O O

Minimum O O
inhibitory O O
concentrations O O
( O O
MICs O O
) O O
and O O
viable O O
counts O O
were O O
determined O O
in O O
Iso O O
- O O
sensitest O O
broth O O
using O O
a O O
microtitre O O
method O O
. O O

Digoxin B-Drug B-Drug
is O O
eliminated O O
renally O O
. O O

Two O O
groups O O
( O O
SH O O
/ O O
DA O O
; O O
SH O O
/ O O
FA O O
) O O
were O O
submitted O O
to O O
daily O O
treatment O O
with O O
synthetic O B-Group
hydroalcoholic O I-Group
solutions O I-Group
containing O O
ethanol B-Drug B-Drug
methanol B-Drug_n O
higher O O
alcohols B-Drug_n O
and O O
acetaldehyde B-Drug_n B-Drug
in O O
the O O
same O O
proportions O O
as O O
those O O
found O O
in O O
most O O
common O O
distilled O O
and O O
fermented O O
alcoholic O O
beverages O O
; O O

A O O
greater O O
understanding O O
of O O
pain O O
mechanisms O O
will O O
aid O O
in O O
elucidating O O
the O O
role O O
of O O
antihistaminics B-Group B-Drug
in O O
analgesia O O
. O O

Although O O
much O O
statistical O O
work O O
has O O
focused O O
on O O
developing O O
mathematical O O
functions O O
to O O
model O O
the O O
joint O O
dose O O
- O O
response O O
curves O O
relatively O O
little O O
work O O
exists O O
in O O
regard O O
to O O
designing O O
experiments O O
for O O
assessing O O
joint O O
action O O
. O O

Administering O O
InsP9 B-Drug_n O
together O O
with O O
RR B-Drug_n B-Drug_n
( O O
9 O O
- O O
9 O O
microM O O
) O O
inhibited O O
InsP O O
( O O
9 O O
) O O
- O O
induced O O
responses O O
( O O
both O O
Ca O O
( O O
9+ O O
) O O
and O O
current O O
responses O O
) O O
in O O
a O O
dose O O
- O O
dependent O O
fashion O O
. O O

Cardiovascular O O
disease O O
is O O
considered O O
in O O
the O O
next O O
chapter O O
and O O
chapter O O
9 O O
presents O O
findings O O
on O O
endometrial O O
ovarian O O
cervical O O
breast O O
and O O
other O O
cancers O O
. O O

Intraventricular O O
injection O O
of O O
naloxone B-Drug B-Drug
at O O
doses O O
of O O
9 O O
to O O
9 O O
micrograms O O
equally O O
antagonized O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
the O O
tail O O
- O O
flick O O
inhibition O O
induced O O
by O O
intraventricular O O
beta B-Drug_n B-Drug_n
- O O
endorphin B-Drug_n B-Drug_n
and O O
morphine B-Drug B-Drug
. O O

RESULTS O O
: O O
Hydrocortisone B-Drug O
elevated O O
salivary O O
cortisol O O
levels O O
produced O O
modest O O
dysphoria O O
and O O
reduced O O
subjects O O
' O O
reports O O
of O O
wanting O O
more O O
drug O O
. O O

These O O
effects O O
of O O
calcium B-Group B-Group
blockers I-Group I-Group
on O O
platelet O O
function O O
and O O
arachidonic O O
acid O O
metabolism O O
could O O
contribute O O
in O O
part O O
to O O
their O O
efficacy O O
in O O
patients O O
with O O
ischemic O O
heart O O
disease O O
. O O

the O O
fourth O O
group O O
served O O
as O O
control O O
and O O
received O O
an O O
equivalent O O
volume O O
of O O
an O O
isocaloric O O
solution O O
of O O
dextrose B-Drug O
. O O

When O O
ouabain B-Drug B-Drug
was O O
applied O O
to O O
the O O
muscle O O
in O O
the O O
presence O O
of O O
phentolamine B-Drug B-Drug
both O O
first O O
and O O
second O O
contractile O O
responses O O
to O O
PTX B-Drug_n B-Drug
were O O
abolished O O
. O O

These O O
included O O
seven O O
cerebrovascular O O
accidents O O
six O O
sudden O O
cardiac O O
deaths O O
three O O
cases O O
of O O
hyperpyrexia O O
eight O O
poisonings O O
of O O
uncertain O O
mechanism O O
and O O
seven O O
cases O O
of O O
medical O O
complications O O
of O O
intravenous O O
injection O O
; O O

These O O
results O O
suggest O O
that O O
DZNep B-Drug_n B-Drug_n
may O O
be O O
exploited O O
therapeutically O O
for O O
a O O
subset O O
of O O
MM O O
. O O

Enhancement O O
of O O
humoral O O
immune O O
responses O O
to O O
inactivated O B-Drug
Newcastle O O
disease O O
and O O
avian B-Group O
influenza I-Group O
vaccines I-Group O
by O O
oral O O
administration O O
of O O
ginseng B-Drug_n B-Group
stem I-Drug_n I-Group
- O O
and B-Drug_n O
- O O
leaf B-Drug_n B-Group
saponins I-Drug_n I-Group
in O O
chickens O O
. O O

Specific O O
and O O
aspecific O O
treatments O O
of O O
magnesium B-Drug B-Drug
depletion O O
are O O
tricky O O
using O O
for O O
example O O
magnesium B-Group B-Drug
sparing I-Group O
diuretics I-Group O
pharmacological O O
doses O O
of O O
vitamin B-Drug O
B9 I-Drug O
physiological O O
doses O O
of O O
vitamin B-Group B-Group
D I-Group I-Group
and O O
of O O
selenium B-Drug O
. O O

Because O O
efficient O O
labeling O O
can O O
be O O
achieved O O
with O O
9 O O
% O O
biocytin O O
with O O
whole O O
- O O
cell O O
recording O O
higher O O
concentrations O O
are O O
contraindicated O O
. O O

However O O
the O O
antagonism O O
of O O
the O O
theophylline B-Drug B-Drug
- O O
induced O O
anxiogenic O O
effects O O
by O O
CGS99 B-Drug_n O
was O O
only O O
observed O O
in O O
the O O
time O O
spent O O
in O O
the O O
light O O
zone O O
and O O
DPCPX B-Drug_n B-Drug
- O O
induced O O
anxiogenic O O
effects O O
were O O
neither O O
reversed O O
by O O
CGS B-Drug O
99 I-Drug O
nor O O
by O O
CPA B-Drug_n O
. O O

Subjects O O
treated O O
with O O
9 O O
mg O O
of O O
dideoxyinosine B-Drug B-Drug
twice O O
daily O O
for O O
9 O O
days O O
received O O
9 O O
mg O O
of O O
azithromycin B-Drug B-Drug
or O O
an O O
equivalent O O
amount O O
of O O
placebo O O
/ O O
day O O
for O O
Days O O
9 O O
to O O
9 O O
. O O

We O O
report O O
the O O
case O O
of O O
an O O
adolescent O O
with O O
altered O O
consciousness O O
caused O O
by O O
carbamazepine B-Drug B-Drug
overdose O O
with O O
a O O
positive O O
tricyclic B-Group O
antidepressant I-Group O
level O O
to O O
alert O O
clinicians O O
to O O
the O O
cross O O
- O O
reactivity O O
of O O
carbamazepine B-Drug B-Drug
with O O
a O O
toxicology O O
screen O O
for O O
tricyclic B-Group B-Group
antidepressants I-Group I-Group
. O O
